



IN THE DISTRICT COURT OF CLEVELAND COUNTY
STATE OF OKLAHOMA

Document split into multiple parts

PART B

STATE OF OKLAHOMA, ex rel.,)
MIKE HUNTER,)
ATTORNEY GENERAL OF OKLAHOMA,)

Plaintiff,)

vs.)

Case No. CJ-2017-816
Judge Thad Balkman

- (1) PURDUE PHARMA L.P.;)
- (2) PURDUE PHARMA, INC.;)
- (3) THE PURDUE FREDERICK COMPANY;)
- (4) TEVA PHARMACEUTICALS USA, INC.;)
- (5) CEPHALON, INC.;)
- (6) JOHNSON & JOHNSON;)
- (7) JANSSEN PHARMACEUTICALS, INC;)
- (8) ORTHO-MCNEIL-JANSSEN)
PHARMACEUTICALS, INC., n/k/a)
JANSSEN PHARMACEUTICALS;)
- (9) JANSSEN PHARMACEUTICA, INC.,)
n/k/a JANSSEN PHARMACEUTICALS, INC.;)
- (10) ALLERGAN, PLC, f/k/a ACTAVIS PLC,)
f/k/a ACTAVIS, INC., f/k/a WATSON)
PHARMACEUTICALS, INC.;)
- (11) WATSON LABORATORIES, INC.;)
- (12) ACTAVIS LLC; and)
- (13) ACTAVIS PHARMA, INC.,)
f/k/a WATSON PHARMA, INC.,)

Defendants.)

STATE OF OKLAHOMA } S.S.
CLEVELAND COUNTY }

FILED

MAY 23 2019

In the office of the
Court Clerk MARILYN WILLIAMS

PRETRIAL CONFERENCE ORDER

EXHIBIT A

**IN THE DISTRICT COURT OF CLEVELAND COUNTY
STATE OF OKLAHOMA**

STATE OF OKLAHOMA, ex rel.,	§	
MIKE HUNTER,	§	
ATTORNEY GENERAL OF OKLAHOMA,	§	
	§	
Plaintiff,	§	
	§	
vs.	§	Case No. CJ-2017-816
	§	The Honorable Thad Balkman
	§	
(1) PURDUE PHARMA L.P.;	§	
(2) PURDUE PHARMA, INC.;	§	William C. Hetherington
(3) THE PURDUE FREDERICK COMPANY;	§	Special Discovery Master
(4) TEVA PHARMACEUTICALS USA, INC.;	§	
(5) CEPHALON, INC.;	§	
(6) JOHNSON & JOHNSON;	§	
(7) JANSSEN PHARMACEUTICALS, INC.;	§	
(8) ORTHO-McNEIL-JANSSEN	§	
PHARMACEUTICALS, INC., n/k/a	§	
JANSSEN PHARMACEUTICALS, INC.;	§	
(9) JANSSEN PHARMACEUTICA, INC.,	§	
n/k/a JANSSEN PHARMACEUTICALS, INC.;	§	
(10) ALLERGAN, PLC, f/k/a ACTAVIS PLC,	§	
f/k/a ACTAVIS, INC., f/k/a WATSON	§	
PHARMACEUTICALS, INC.;	§	
(11) WATSON LABORATORIES, INC.;	§	
(12) ACTAVIS LLC; and	§	
(13) ACTAVIS PHARMA, INC.,	§	
f/k/a WATSON PHARMA, INC.,	§	
	§	
Defendants.	§	

THE STATE'S TRIAL WITNESS LIST

In compliance with the Court's Scheduling Order, below is the State's Trial Witness List.¹

The list does not include witnesses that the State may call by deposition designation or for impeachment.

¹ The State reserves the right to update this list should it discover the existence of additional relevant witnesses that Defendants have failed to disclose. The State also reserves the right to call any witnesses live that Defendants bring to trial.

Last	First	Title/Subject	Contact
Abraham	Craig	Former J&J Sales Employee	J&J Defendants
Abraham	Holly	Former J&J Sales Representative	J&J Defendants
Auer	Keith	Former J&J Sales Representative	J&J Defendants
Baeder	Christine	Teva employee - See deposition	Teva Defendants
Barnhouse	Jenny	Peer Assistance Program Coordinator Oklahoma Board of Nursing - See deposition	State's Counsel
Beaman	Jason	See expert disclosure and depositions	State's Counsel
Beasley	Burl	Director of Pharmacy Operations Oklahoma Health Care Authority - See depositions	State's Counsel
Box	Craig	See deposition	State's Counsel
Buel	Jeff	J&J employee - See deposition	J&J Defendants
Butterfield	Steven	J&J employee	J&J Defendants
Cambra	Lauren	See deposition	See deposition
Chupa	Kati	Former J&J employee	J&J Defendants
Clauw	Daniel	See expert disclosure and deposition	State's Counsel
Colligen	Bruce	J&J employee - See deposition	J&J Defendants
Costa	Pamela	Teva sales representative - See deposition	Teva Defendants
Courtwright	David	See expert disclosure and deposition	State's Counsel
Cramer	Phil	Purdue Employee and Corporate Representative - See deposition	Purdue Defendants
Crawford	Stephen	Chairman of OU Health Sciences Center - See deposition	State's Counsel
Croff	Julie	See expert disclosure and deposition	State's Counsel
Curtis	Byron	Chief Toxicologist Office of Chief Medical Examiner - See deposition	State's Counsel
Day	Jason	J&J Sales Representative	J&J Defendants
Deem-Eshleman	Kimberly	J&J employee	J&J Defendants
Deem-Eshleman	Kimberly	J&J corporate representative	J&J Defendants
Dickson	Melinda	J&J Sales Representative	J&J Defendants
Diesselhorst	Drue	Former J&J Sales Representative	J&J Defendants

Diesselhorst	Rebecca	Former J&J Sales Representative	J&J Defendants
Duncan	John	See expert disclosure and deposition	State's Counsel
Everly	David	Former J&J Sales Representative	State's Counsel
Fishman	Scott	See deposition	John Robinson, Gorden Rees Scully Mansukhani LLP
Flanary	Jason	J&J employee - See deposition	J&J Defendants
Fugh-Berman	Adrian	See expert disclosure and deposition	State's Counsel
Gibson	Jim	See expert disclosure and deposition	State's Counsel
Gilson	Aaron	See deposition	Gesina Carson, Assistant Attorney General, Wisconsin
Griffith	Ty	See expert disclosure and deposition	State's Counsel
Grubb	Bill	Noramco Employee - See deposition	Daniel Jarcho, Alston & Bird LLP
Guthrie	William	Former J&J Sales Representative	J&J Defendants
Hague	Kelly	J&J employee	J&J Defendants
Hassler	John	Teva Employee - See deposition	Teva Defendants
Hassler	John	Teva Corporate Representative - See depositions	Teva Defendants
Hawkins	Jessica	See expert disclosure and deposition	State's Counsel
Herndon	Mike	Chief Medical Officer, Oklahoma Health Care Authority - See depositions	State's Counsel
Hightower	Elizabeth	Former J&J Sales Representative - See deposition	J&J Defendants
Holderread	Bethany	Pharmacy Management Consultants, OU College of Pharmacy - See deposition	State's Counsel
Hoos	Kristi	See deposition	State's Counsel
Howard	Stephen	Former J&J Sales Representative - See deposition	J&J Defendants
Keast	Shellie	Oklahoma College of Pharmacy - See deposition	State's Counsel
Kolodny	Andrew	See expert disclosure and deposition	State's Counsel
Kuntz	Ronald	J&J Employee - See deposition	J&J Defendants

Kyle	Donald	Purdue employee - See deposition	Purdue Defendants
Larijani	Susan	Teva employee - See deposition	State's Counsel
Lockhart	Angela	Former J&J Sales Representative - See deposition	J&J Defendants
Martin	Sam	See expert disclosure and deposition	State's Counsel
Mashett	Frank	J&J employee - See deposition	J&J Defendants
Mashett	Frank	J&J corporate representative - See deposition	J&J Defendants
Mazloomdoost	Danesh	See expert disclosure and deposition	State's Counsel
McAllister	Bill	See expert disclosure and deposition	State's Counsel
McClure	Melynda	Former J&J Sales Representative - See deposition	J&J Defendants
McGregor	John	See deposition	State's Counsel
Medina	Mark	Former J&J Sales Representative - See deposition	J&J Defendants
Mendell	Gary	See expert disclosure and deposition	State's Counsel
Miller	Lisa	Purdue employee - See deposition	Purdue Defendants
Miller	Matthew	Noramco employee - See deposition	Daniel Jarcho, Alston & Bird LLP
Moskovitz	Bruce	J&J employee - See deposition	J&J Defendants
Mosley	Thomas	Former Teva Sales Representative - See deposition	Teva Defendants
Mullen	Tim	Former Teva Sales Representative - See deposition	Teva Defendants
Must	Alan	Purdue employee - See deposition	Purdue Defendants
Nguyen	Claire	See expert disclosure and deposition	State's Counsel
Panico	Greg	J&J employee	J&J Defendants
Pfeifer	Eric	Chief Medical Examiner - See deposition	State's Counsel
Ponder	Richard	J&J employee	J&J Defendants
Portenoy	Russell	See deposition	S. Amy Spencer, Shaheen Gordon
Radcliffe	Tonya	See deposition	State's Counsel

Robin	Lisa	FSMB - See deposition	Eric Fish, 1300 Connecticut Ave, NW Suite 500, Washington, DC 20036
Robyn	Kohn	Former J&J employee - See deposition	J&J Defendants
Rojas	Julio	See expert disclosure and deposition	State's Counsel
Rosen	Burt	Purdue employee - See deposition	Purdue Defendants
Ruhm	Chris	See expert disclosure and deposition	State's Counsel
Samples	Joanna	J&J Sales Representative	J&J Defendants
Sharp	Susan	See expert disclosure and deposition	State's Counsel
Stewart	Mark	Chief Agent of Enforcement, OBN - See deposition	State's Counsel
Stone	Renzi	See expert disclosure and deposition	State's Counsel
Tate	Travis	Director of Pharmacy, HealthChoice - See deposition	State's Counsel
Thornhill	Eric	Former J&J Sales Representative	J&J Defendants
Tilley	David	Former J&J Sales Representative - See deposition	J&J Defendants
Trindle	Angela	J&J employee	J&J Defendants
VanBurkelo	Kelly	J&J employee	J&J Defendants
Vaughan	Brian	Teva sales representative - See deposition	Teva Defendants
Verheyen	Patrick	J&J employee - See deposition	J&J Defendants
Vorsanger	Gary	J&J employee - See deposition	J&J Defendants
Wakefield	Elizabeth	Former J&J Sales Representative - See deposition	J&J Defendants
Wayman	Eric	Former Purdue Sales Employee - See deposition	Purdue Defendants
White	Terri	See expert disclosure and deposition	State's Counsel
Williams	Paula	Teva employee - See deposition	Teva Defendants
Woodward	Mark	Education Officer and Legislative Liaison, OBN - See deposition	State's Counsel
<i>Corporate Representative(s) of the State of Oklahoma</i>			
<i>Corporate Representative(s) of J&J Defendants</i>			

Corporate Representative(s) of Teva Defendants
--

Any fact or expert witnesses brought to trial by any Defendant
--

Respectfully submitted,

s/ Michael Burrage

Michael Burrage, OBA No. 1350

Reggie Whitten, OBA No. 9576

WHITTEN BURRAGE

512 N. Broadway Avenue, Suite 300

Oklahoma City, OK 73102

Telephone: (405) 516-7800

Facsimile: (405) 516-7859

Emails: mburrage@whittenburrage.com

rwhitten@whittenburrage.com

Mike Hunter, OBA No. 4503

ATTORNEY GENERAL FOR

THE STATE OF OKLAHOMA

Abby Dillsaver, OBA No. 20675

GENERAL COUNSEL TO

THE ATTORNEY GENERAL

Ethan A. Shaner, OBA No. 30916

DEPUTY GENERAL COUNSEL

313 N.E. 21st Street

Oklahoma City, OK 73105

Telephone: (405) 521-3921

Facsimile: (405) 521-6246

Emails: abby.dillsaver@oag.ok.gov

ethan.shaner@oag.ok.gov

Bradley E. Beckworth, OBA No. 19982

Jeffrey J. Angelovich, OBA No. 19981

Trey Duck, OBA No. 33347

Drew Pate, *pro hac vice*

NIX PATTERSON, LLP

512 N. Broadway Avenue, Suite 200

Oklahoma City, OK 73102

Telephone: (405) 516-7800

Facsimile: (405) 516-7859

Emails: bbeckworth@nixlaw.com

jangelovich@nixlaw.com

Glenn Coffee, OBA No. 14563
GLENN COFFEE & ASSOCIATES, PLLC
915 N. Robinson Ave.
Oklahoma City, OK 73102
Telephone: (405) 601-1616
Email: gcoffee@glenncoffee.com

ATTORNEYS FOR PLAINTIFF

CERTIFICATE OF SERVICE

I certify that a true and correct copy of the above and foregoing was emailed on April 26, 2019, to:

Patrick J. Fitzgerald
R. Ryan Stoll
SKADDEN, ARPS, SLATE, MEAGHER &
FLOM LLP
155 North Wacker Drive, Suite 2700
Chicago, Illinois 60606

Robert G. McCampbell
Nicholas Merkley
GABLEGOTWALS
One Leadership Square, 15th Floor
211 North Robinson
Oklahoma City, OK 73102-7255

Steven A. Reed
Harvey Bartle IV
Jeremy A. Menkowitz
MORGAN, LEWIS & BOCKIUS LLP
1701 Market Street
Philadelphia, PA 19103-2921

Brian M. Ercole
MORGAN, LEWIS & BOCKIUS LLP
200 S. Biscayne Blvd., Suite 5300
Miami, FL 33131

Benjamin H. Odom
John H. Sparks
Michael Ridgeway
David L. Kinney
ODOM, SPARKS & JONES PLLC
HiPoint Office Building
2500 McGee Drive Ste. 140
Oklahoma City, OK 73072

Charles C. Lifland
Jennifer D. Cardelus
Wallace Moore Allan
O'MELVENY & MYERS LLP
400 S. Hope Street
Los Angeles, CA 90071

Stephen D. Brody
David Roberts
O'MELVENY & MYERS LLP
1625 Eye Street NW
Washington, DC 20006

Larry D. Ottaway
Amy Sherry Fischer
FOLIART, HUFF, OTTAWAY & BOTTOM
201 Robert S. Kerr Ave, 12th Floor
Oklahoma City, OK 73102

Daniel J. Franklin
Ross Galin
O'MELVENY & MYERS LLP
7 Time Square
New York, NY 10036

s/ Michael Burrage

Michael Burrage

EXHIBIT B

**IN THE DISTRICT COURT OF CLEVELAND COUNTY
STATE OF OKLAHOMA**

STATE OF OKLAHOMA, ex rel.,
MIKE HUNTER,
ATTORNEY GENERAL OF OKLAHOMA,

Plaintiff,

vs.

- (1) PURDUE PHARMA L.P.;
- (2) PURDUE PHARMA, INC.;
- (3) THE PURDUE FREDERICK COMPANY;
- (4) TEVA PHARMACEUTICALS
USA, INC.;
- (5) CEPHALON, INC.;
- (6) JOHNSON & JOHNSON;
- (7) JANSSEN PHARMACEUTICALS, INC.;
- (8) ORTHO-McNEIL-JANSSEN
PHARMACEUTICALS, INC., n/k/a
JANSSEN PHARMACEUTICALS, INC.;
- (9) JANSSEN PHARMACEUTICA, INC.,
n/k/a JANSSEN PHARMACEUTICALS,
INC.;
- (10) ALLERGAN, PLC, f/k/a ACTAVIS PLC,
f/k/a ACTAVIS, INC., f/k/a WATSON
PHARMACEUTICALS, INC.;
- (11) WATSON LABORATORIES, INC.;
- (12) ACTAVIS LLC; and
- (13) ACTAVIS PHARMA, INC.,
f/k/a WATSON PHARMA, INC.,

Defendants.

Case No. CJ-2017-816

Honorable Thad Balkman

**DEFENDANTS CEPHALON, INC., TEVA PHARMACEUTICALS USA, INC.,
WATSON LABORATORIES, INC., ACTAVIS LLC, AND ACTAVIS PHARMA, INC.
f/k/a WATSON PHARMA INC.'S TRIAL WITNESS LIST**

Pursuant to the Court's April 18, 2019 Scheduling Order, Defendants Cephalon, Inc. and Teva Pharmaceuticals USA, Inc. ("Teva USA") (collectively, the "Teva Defendants") and Watson Laboratories, Inc., Actavis LLC, and Actavis Pharma, Inc. f/k/a Watson Pharma, Inc. (collectively, the "Acquired Actavis Entities") by and through their undersigned counsel, hereby submit the following list of witnesses that they expect to call or may call if needed at trial:

A. Witnesses that the Teva Defendants and Acquired Actavis entities expect to call live at trial:

Name	Title	Contact Info.	Subject Matter
Christine Baeder	Teva Pharmaceuticals Chief Operations Officer, US Generics	To be contacted only through Morgan, Lewis & Bockius LLP	Deposed
Pradeep Chintagunta	Expert Witness	To be contacted only through Morgan, Lewis & Bockius LLP	Deposed
Michael Confer	Expert Witness	To be contacted only through Morgan, Lewis & Bockius LLP	See Expert Disclosure
Pamela Costa	Teva Pharmaceuticals Sales Representative	To be contacted only through Morgan, Lewis & Bockius LLP	Deposed
Tricia Glover	Teva Pharmaceuticals Vice President, US Chief Compliance Officer	To be contacted only through Morgan, Lewis & Bockius LLP	Compliance
John Hassler	Teva Pharmaceuticals Senior Vice President and General Manager, CNS	To be contacted only through Morgan, Lewis & Bockius LLP	Deposed

Jonathan Ketchum	Expert Witness	To be contacted only through Morgan, Lewis & Bockius LLP	Deposed
Edward Michna	Expert Witness	To be contacted only through Morgan, Lewis & Bockius LLP	Deposed
Sean Nicholson	Expert Witness	To be contacted only through Morgan, Lewis & Bockius LLP	Deposed
Melanie Rosenblatt	Expert Witness	To be contacted only through Morgan, Lewis & Bockius LLP	Deposed

B. Witnesses that the Teva Defendants and Acquired Actavis entities may call at trial if the need arises:

Name	Title	Contact Info.	Subject Matter
Deborah Bearer	Teva Pharmaceuticals Director, Health Systems Marketing	To be contacted only through Morgan, Lewis & Bockius LLP	Deposed
Valli Baldassano	Former Cephalon Executive Vice President & Chief Compliance Officer	To be contacted only through Morgan, Lewis & Bockius LLP	Compliance
Stacey Beckhardt	Former Cephalon Associate Director, Alliance Development	To be contacted only through Morgan, Lewis & Bockius LLP	Medical education grants
Joseph Caminiti	Former Cephalon Inc., Vice President, Sales and Marketing Operations and Effectiveness	To be contacted only through Morgan, Lewis & Bockius LLP	Sales, marketing, and managed care issues

Cynthia Condodina	Teva Pharmaceuticals Director, Commercial Training & Development	To be contacted only through Morgan, Lewis & Bockius LLP	Deposed
Matthew Day	Teva Pharmaceuticals Director, Marketing, CNS & Pain Care Franchises	To be contacted only through Morgan, Lewis & Bockius LLP	Marketing issues
Joyce DelGaudio	Teva Pharmaceuticals Senior Director, Regulatory Affairs Pre Approval, Generic	To be contacted only through Morgan, Lewis & Bockius LLP	Regulatory affairs
Chuck DeWildt	Former Teva Pharmaceuticals Vice President, Regional Payers	To be contacted only through Morgan, Lewis & Bockius LLP	Sales Training
Chris Doerr	Teva Pharmaceuticals Vice President, Trade Relations & Distribution Strategy	To be contacted only through Morgan, Lewis & Bockius LLP	Sales to distributors/trade customers
Kishore Gopu	Teva Pharmaceuticals Director of REMS	To be contacted only through Morgan, Lewis & Bockius LLP	Risk management and REMS programs
Dolly Judge	Teva Pharmaceuticals Vice President, U.S. Government Affairs	To be contacted only through Morgan, Lewis & Bockius LLP	Deposed
Jerry Kester	Teva Pharmaceuticals Director of Trade Strategy and Former Associate Director, REM Operations	To be contacted only through Morgan, Lewis & Bockius LLP	Risk management and REMS Programs
James G. King	Teva Pharmaceuticals Director, US Medical Information	To be contacted only through Morgan, Lewis & Bockius LLP	TIRF REMS & Medical Affairs

Ernest Kopecky	Teva Pharmaceuticals Vice President, Clinical Development; Head, Global Pain Medicine	To be contacted only through Morgan, Lewis & Bockius LLP	Medical Affairs
Susan Larijani	Teva Pharmaceuticals Senior Director, Medical Information	To be contacted only through Morgan, Lewis & Bockius LLP	Deposed
Penny Levine	Former Teva Pharmaceuticals Director, Regulatory Affairs	To be contacted only through Morgan, Lewis & Bockius LLP	Regulatory Affairs, risk management, and REMS programs
Karen Lowney	Former Teva Pharmaceuticals Senior Director, Global Compliance	To be contacted only through Morgan, Lewis & Bockius LLP	Compliance
Carole Marchione	Former Teva Pharmaceuticals Senior Director and Group Leader for Oncology Regulatory Affairs	To be contacted only through Morgan, Lewis & Bockius LLP	Regulatory affairs and submissions to FDA
Sheila Mathias	Teva Pharmaceuticals Director, Regulatory Affairs	To be contacted only through Morgan, Lewis & Bockius LLP	Risk management planning and drug development process
Chris Meyer	Teva Pharmaceuticals Director, Sales Force Planning & Operations	To be contacted only through Morgan, Lewis & Bockius LLP	Sales and promotional practices
David Myers	Teva Pharmaceuticals Senior Manager, Product Marketing	To be contacted only through Morgan, Lewis & Bockius LLP	Marketing issues
Alex Nikas	Teva Pharmaceuticals Senior Director, Executive Counsel	To be contacted only through Morgan, Lewis & Bockius LLP	Marketing issues

Andrew Pyfer	Former Cephalon National Sales Director, Pain Care Division	To be contacted only through Morgan, Lewis & Bockius LLP	Sales and promotional practices
James Reilly	Former Teva Pharmaceuticals Vice President, Sales	To be contacted only through Morgan, Lewis & Bockius LLP	Sales and promotional practices
Kate Reedy	Former Teva Pharmaceuticals Sales Operations Manager	To be contacted only through Morgan, Lewis & Bockius LLP	Sales Operations
Michael Richardson	Former Cephalon Senior Director of Product Planning for Pain Franchise	To be contacted only through Morgan, Lewis & Bockius LLP	Marketing issues
Randy Spokane	Former Teva Pharmaceuticals National Sales Director, pain Care	To be contacted only through Morgan, Lewis & Bockius LLP	Sales and promotional practices
Terrance Terifay	Former Cephalon Product Director, FENTORA®	To be contacted only through Morgan, Lewis & Bockius LLP	Marketing issues
Jerri Ann Thatcher	Former Cephalon Senior Director, Pain Franchise Marketing	To be contacted only through Morgan, Lewis & Bockius LLP	Marketing issues
Joe Tomkiewicz	Teva Pharmaceuticals Manager, DEA Compliance	To be contacted only through Morgan, Lewis & Bockius LLP	DEA compliance
Jamie Warner	Teva Pharmaceuticals Vice President, Global Labeling and Brand Management	To be contacted only through Morgan, Lewis & Bockius LLP	Product labeling

Brian Vaughn	Teva Pharmaceuticals Regional Sales Manger	To be contacted only through Morgan, Lewis & Bockius LLP	Deposed
Paula Williams	Teva Pharmaceuticals Director, Medical Education	To be contacted only through Morgan, Lewis & Bockius LLP	Deposed
Marais, Laurentius	Expert Witness	To be contacted only through O'Melveny & Myers LLP	See Expert Disclosure
Halford, Jeffrey (DO)	Physician - Pain Management of Oklahoma	9308 S. Toledo Ave, Tulsa, OK 74137	Deposed
Ollar-Shoemake, Leslie	Physician	3440 R.C. Luttrell Dr., Norman, OK 73072	Deposed
Schick, Gary (MD)	Physician, McBride Orthopedic	9600 Broadway Ext, Oklahoma City, OK 73114	Deposed
Brown, Nate	Director of Programming, OK Department of Corrections	State Witness	Deposed
Curtis, Byron Ph.D., F-ABFT	Chief Toxicologist, Oklahoma Office of the Chief Medical Examiner	State Witness	Deposed
Hamilton-Fain, Cindy	Pharmacist, Chief Compliance Officer, OK State Board of Pharmacy	State Witness	Deposed
Herndon, Michael	Chief Medical Officer, OK Health Care Authority	State Witness	Deposed

McCurdy, Joel M.D.	Chief Medical Officer, OK Department of Corrections	State Witness	Deposed
Muchmore, John	Current member of the Drug Utilization Board (DURB), OK State Healthcare	State Witness	Deposed
Murphy, Robin	Director of Pharmacy, OK Department of Corrections	State Witness	Deposed
Nesser, Nancy	Pharmacy Director, Oklahoma Health Care Authority	State Witness	Deposed
Pfeifer, Eric	Chief Medical Examiner, State of OK	State Witness	Deposed
Weaver, Darrell	Former OBN Director and State Senator	State Witness	Deposed
Woodward, Mark	Bureau of Narcotics & Dangerous Drugs Control	State Witness	Deposed
All current and former employees of the Teva Defendants and/or Acquired Actavis Entities noticed or subpoenaed for deposition or trial in this action.			
All witnesses yet to be deposed in this matter as of April 26, 2019.			
All witnesses that Janssen Pharmaceuticals, Inc., Ortho-McNeil Pharmaceuticals, Inc., Janssen Pharmaceutica, Inc., and Johnson & Johnson identified in their March 1, 2019 Supplemental Disclosures and their April 26, 2019 Witness List.			

This list does not include witnesses that the Teva Defendants and the Acquired Actavis Entities may call by deposition designation or for impeachment. This list is based on information reasonably available to the Teva Defendants and Acquired Actavis Entities and is provided without prejudice to the right to supplement, modify, change, or amend.

Dated: April 26, 2019

By: /s/ Nicholas v. Merkley

Nicholas V. Merkley, OBA NO. 20284
Robert G. McCampbell, OBA No. 10390
Ashley E. Quinn OBA No. 20284
GABLEGOTWALS
One Leadership Square, 15th Fl.
211 North Robinson
Oklahoma City, OK 73102-7255
T: +1.405.235.5567
Email: RMcCampbell@Gablelaw.com
Email: NMerkley@Gablelaw.com
Email: AQuinn@Gablelaw.com

OF COUNSEL:

Steven A. Reed
Harvey Bartle IV
Mark A. Fiore
MORGAN, LEWIS & BOCKIUS LLP
1701 Market Street
Philadelphia, PA 19103-2921
T: +1.215.963.5000
Email: harvey.bartle@morganlewis.com
Email: steven.reed@morganlewis.com
Email: mark.fiore@morganlewis.com

Nancy L. Patterson
1000 Louisiana St., Suite 4000
Houston, TX 77002-5006
T: +1.713.890.5195
E-mail: nancy.patterson@morganlewis.com

Brian M. Ercole
Martha Leibell
MORGAN, LEWIS & BOCKIUS LLP
200 S. Biscayne Blvd., Suite 5300
Miami, FL 33131
T: +1.305.415.3416
Email: brian.ercole@morganlewis.com
Email: martha.leibell@morganlewis.com

*Attorneys for Defendants Cephalon, Inc.,
Teva Pharmaceuticals USA, Inc., Watson
Laboratories, Inc., Actavis LLC, and Actavis
Pharma, Inc. f/k/a Watson Pharma, Inc.*

CERTIFICATE OF SERVICE

I hereby certify that on this 26th day of April, 2019, I caused a true and correct copy of the following:

DEFENDANTS CEPHALON, INC., TEVA PHARMACEUTICALS USA, INC., WATSON LABORATORIES, INC., ACTAVIS LLC, AND ACTAVIS PHARMA, INC. f/k/a WATSON PHARMA INC.'S TRIAL WITNESS LIST

to be served upon the counsel of record listed on the attached service list via electronic mail.

/s/ Nicholas v. Merkley

SERVICE LIST

WHITTEN BURRAGE

Michael Burrage
Reggie Whitten
512 N. Broadway Avenue, Suite 300
Oklahoma City, OK 73102
mburrage@whittenburrage.com
rwhitten@whittenburrage.com
Phone: (405) 516-7800
Fax: (405) 516-7859

Counsel for Plaintiff the State of Oklahoma

NIX, PATTERSON & ROACH, LLP

Bradley E. Beckworth
Jeffrey J. Angelovich
512 N. Broadway Ave., Suite 200
Oklahoma City, OK 73102
bbeckworth@nixlaw.com
jangelovich@nprustin.com
Phone: (405) 516-7800
Fax: (405) 516-1616

Counsel for Plaintiff the State of Oklahoma

OKLAHOMA OFFICE OF THE ATTORNEY GENERAL

Mike Hunter
Abby Dillsaver
Ethan A. Shaner
313 NE 21st St
Oklahoma City, OK 73105
abby.dillsaver@oag.ok.gov
ethan.shaner@oag.ok.gov
Phone: (405) 521-3921
Fax: (405) 521-6246

*Counsel for Plaintiff the State of
Oklahoma*

GLENN COFFEE & ASSOCIATES, PLLC

Glenn Coffee
915 N. Robinson Ave.
Oklahoma City, OK 73102
gcoffee@glenncoffee.com
Phone: (405) 601-1616

*Counsel for Plaintiff the State of
Oklahoma*

EXHIBIT C

IN THE DISTRICT COURT OF CLEVELAND COUNTY

STATE OF OKLAHOMA

STATE OF OKLAHOMA, ex rel.,
MIKE HUNTER,
ATTORNEY GENERAL OF OKLAHOMA,

Plaintiff,

vs.

PURDUE PHARMA L.P., et al.,

Defendants.

Case No. CJ-2017-816

Honorable Thad Balkman

JOHNSON & JOHNSON AND JANSSEN'S WITNESS LIST

Pursuant to the Court's April 11, 2019 Order and April 18, 2019 Updated Scheduling Order, Janssen Pharmaceuticals, Inc., its predecessor companies Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica, Inc. (jointly, "Janssen"), and its parent company Johnson & Johnson ("J&J") submit the following list of witnesses that they expect to call or may call live or by designation if needed during their case in chief.

1. Charles Argoff, MD
Professor of Neurology, Albany Medical Center
Director, Comprehensive Pain Center
Contact information: Christopher Fenlon
Hinckley Allen
30 South Pearl Street, Suite 901
Albany, NY 12207
2. Demetra Ashley
Former Acting Assistant Administrator, Office of Diversion Control
Drug Enforcement Administration
Contact information: David Finkelstein
United States Department of Justice
David.M.Finkelstein@usdoj.gov

Ms. Ashley is formerly the Acting Assistant Administrator in the Office of Diversion Control at the DEA. Janssen anticipates that she will testify about DEA's interpretation and enforcement of, and practices related to, the Controlled Substances Act and its implementing regulations.

3. Jenny Barnhouse
Program Coordinator for the Oklahoma Peer Assistance Program
Oklahoma Board of Nursing
Contact information: Counsel of record for the State of Oklahoma
4. Tom Bates
Interim Commissioner of Health
Oklahoma State Department of Health
Contact information: Counsel of record for the State of Oklahoma
5. Jason Beaman, D.O., M.S., M.P.H., FAPA
Chair, Department of Psychiatry and Behavioral Sciences
Oklahoma State University Center for Health Sciences
Contact information: Counsel of record for the State of Oklahoma
6. Burl Beasley
Pharmacy Director
Oklahoma Health Care Authority
Contact information: Counsel of record for the State of Oklahoma
7. Andrew Briggeman, D.O.
Contact information: Jim Connor
Richards & Connor
(918) 585-2394

Dr. Briggeman is a physician whose records Dr. Jason Beaman reviewed as part of his analysis for this action. Janssen anticipates Dr. Briggeman will testify about the prescribing and use of prescription opioid medications for chronic pain for those patients whose records were identified and/or reviewed by Dr. Beaman.
8. Nathan Brown
Director of Programs
Oklahoma Department of Corrections
Contact information: Counsel of record for the State of Oklahoma
9. Deborah Bruce
Executive Director
Oklahoma State Board of Osteopathic Examiners
Contact information: Counsel of record for the State of Oklahoma
10. Clint Castleberry
Director of Health Services
Oklahoma Department of Corrections
Contact information: Counsel of record for the State of Oklahoma
11. Kati Chupa
Former Vice President of Primary Care Marketing
Janssen
Contact information: Counsel of record for J&J and Janssen

12. Bruce Colligen
Executive Director, Health Policy
J&J
Contact information: Counsel of record for J&J and Janssen
13. Terry Cothran
Director
Pharmacy Management Consultant, University of Oklahoma College of Pharmacy
Contact information: Counsel of record for the State of Oklahoma
14. Byron Curtis
Chief Toxicologist and Laboratory Director
Office of the Chief Medical Examiner
Contact information: Counsel of record for the State of Oklahoma
15. Michael D'Agati
Senior Director, Corporate Development
Janssen
Contact information: Counsel of record for J&J and Janssen
16. Kimberly Deem-Eshleman¹
Regional Business Director
Janssen
Contact information: Counsel of record for J&J and Janssen
17. Michele Dempsey
Director, Controlled Substances Compliance, J&J
Contact information: Counsel of record for J&J and Janssen
Ms. Dempsey is currently the Director of Controlled Substance Compliance at Janssen. Janssen anticipates she will testify about suspicious order monitoring policies, practices, and procedures.
18. John Duncan, Ph.D.
Assistant Professor of Interdisciplinary Studies and Cultural Studies
University of Oklahoma, College of Liberal Studies
Contact information: Counsel of record for the State of Oklahoma
19. Melton Edminsten
Investigator
Oklahoma State Board of Veterinary Medical Examiners
Contact information: Counsel of record for the State of Oklahoma

¹ Ms. Deem-Eshleman will serve as a representative witness who will be available during the State's case in chief upon reasonable notice.

20. Karen Egesdal
Coordinator, Prospective Drug Utilization Review
Pharmacy Management Consultant, University of Oklahoma College of Pharmacy
Contact information: Counsel of record for the State of Oklahoma
21. Cindy Fain
Inspector, Arkansas Board of Pharmacy
Contact information: Counsel of record for the State of Oklahoma
22. Scott Fishman, MD
Chair of Pain Medicine
University of California Davis Division of Pain Medicine
Contact information: John Robinson
Gordon & Rees Scully Mansukhani
95 Glastonbury Boulevard, Suite 206
Glastonbury, CT 06033
23. Jason Flanary
Senior District Manager
Janssen
Contact information: Counsel of record for J&J and Janssen
24. Jill Geiger
State Budget Director
Contact information: Counsel of record for the State of Oklahoma
25. James Gibson, PhD
Professor of Government, Washington University at St. Louis
Contact information: Counsel of record for the State of Oklahoma
26. William Grubb
Vice President, Business Development and Innovation
Noramco
Contact information: Cari Dawson
Alston & Bird
One Atlantic Center
1201 West Peachtree Street
Atlanta, GA 30309-3434
27. Jeff Halford, D.O.
Oklahoma Physician/Owner
Pain Management of Oklahoma
Contact information: Tulsa, Oklahoma

28. Stacy Harper-Avilla
Chief, UN Reporting and Quota Section, Diversion Control Division
Drug Enforcement Administration
Contact information: David Finkelstein
United States Department of Justice
David.M.Finkelstein@usdoj.gov
Ms. Harper-Avilla is the current Chief of the UN Reporting and Quota Section in the Diversion Control Division at the DEA. Janssen anticipates she will testify about DEA's interpretation and enforcement of, and practices related to, the Controlled Substances Act and its implementing regulations.
29. Anetta Harrell
Clinical Service Coordinator
St. Anthony's Hospital
Contact information: Counsel of record for the State of Oklahoma
30. Jessica Hawkins
Director of Prevention Services
Oklahoma Department of Mental Health and Substance Abuse Services
Contact information: Counsel of record for the State of Oklahoma
31. Mike Herndon
Chief Medical Officer
Oklahoma Health Care Authority
Contact information: Counsel of record for the State of Oklahoma
32. Bethany Holderread, Pharm.D.
Clinical Coordinator
Pharmacy Management Consultant, University of Oklahoma College of Pharmacy
Contact information: Counsel of record for the State of Oklahoma
33. June Howard
Chief, Targeting and Analysis Unit of the Pharmaceutical Investigation Section
Drug Enforcement Administration
Contact information: David Finkelstein
United States Department of Justice
David.M.Finkelstein@usdoj.gov
Ms. Howard is the Chief of the Targeting and Analysis Unit in the Pharmaceuticals Investigation Section at the DEA. Janssen anticipates she will testify about DEA's interpretation and enforcement of, and practices related to, the Controlled Substances Act and its implementing regulations.
34. Shellie Keast
Assistant Professor
University of Oklahoma College of Pharmacy
Contact information: Counsel of record for the State of Oklahoma

35. Ron Kuntz
Product Director
Janssen
Contact information: Counsel of record for J&J and Janssen
36. Frank Lawler
Chief Medical Officer, Employees Group Insurance Division
Office of Management and Enterprise Services for the State of Oklahoma
Contact information: Counsel of record for the State of Oklahoma
37. Keith Martin
Assistant Special Agent in Charge
Drug Enforcement Administration
Contact information: David Finkelstein
United States Department of Justice
David.M.Finkelstein@usdoj.gov
Mr. Martin is the current Assistant Special Agent in Charge for the DEA. Janssen anticipates that he will testify about DEA's interpretation and enforcement of, and practices related to, the Controlled Substances Act and its implementing regulations.
38. Matthew Martin
Noramco
Contact information: Cari Dawson
Alston & Bird
One Atlantic Center
1201 West Peachtree Street
Atlanta, GA 30309-3434
39. Joel McCurdy
Chief Medical Officer
Oklahoma Department of Corrections
Contact information: Counsel of record for the State of Oklahoma
40. Roxanne McGregor-Beck
Director of Regulatory Advertising & Promotion
Janssen
Contact information: Counsel of record for J&J and Janssen
41. Jessica McGuire
PMP Administrator
Oklahoma Bureau of Narcotics
Contact information: Counsel of record for the State of Oklahoma

42. Matthew Minardi
Noramco
Contact information: Cari Dawson
Alston & Bird
One Atlantic Center
1201 West Peachtree Street
Atlanta, GA 30309-3434
43. Bruce Moskovitz, M.D.
Former Therapeutic Area Head
Janssen
Contact information: Counsel of record for J&J and Janssen.
44. John Muchmore
Chairman
Drug Utilization Review Board
Contact information: INTEGRIS Endocrinology North
3433 NW 56th Street
Bldg. B, Suite 710
Oklahoma City, OK 73112
45. Robin Murphy
Pharmacy Director
Oklahoma Department of Corrections
Contact information: Counsel of record for the State of Oklahoma
46. Nancy Nesser
Pharmacy Director
Oklahoma Health Care Authority
Contact information: Counsel of record for the State of Oklahoma
47. Claire Nguyen
Epidemiologist
Oklahoma State Dept. Health
Contact information: Counsel of record for the State of Oklahoma
48. Leslie Ollar-Shoemake
OB/GYN
Norman Regional Health Systems
Contact information: Norman, OK
49. James Osborne
Board Member
Drug Utilization Review Board
Contact information: Counsel of record for the State of Oklahoma

50. Becky Pasternik-Ikard
Chief Executive Officer
Oklahoma Health Care Authority
Contact information: Counsel of record for the State of Oklahoma
51. Greg Panico
Therapeutic Area Communications Leader
Janssen
Contact information: Counsel of record for J&J and Janssen
52. Eric Pfeifer
Chief Medical Examiner
Oklahoma Office of the Chief Medical Examiner
Contact information: Counsel of record for the State of Oklahoma
53. Paul Preslar
Vice Chair
Drug Utilization Review Board, Oklahoma Health Care Authority
Contact information: Counsel of record for the State of Oklahoma
54. Thomas Prevoznik
Associate Section Chief, Pharmaceuticals Investigations Section
Drug Enforcement Administration
Contact information: David Finkelstein
United States Department of Justice
David.M.Finkelstein@usdoj.gov
Mr. Prevoznik is the current Associate Section Chief in the Pharmaceuticals Investigations Section at the DEA. Janssen anticipates he will testify about DEA's interpretation and enforcement of, and practices related to, the Controlled Substances Act and its implementing regulations.
55. Joseph Rannazzisi
Deputy Assistant Administrator, Office of Diversion Control
Drug Enforcement Administration
Contact information: David Finkelstein
United States Department of Justice
David.M.Finkelstein@usdoj.gov
Mr. Rannazzisi is the former Deputy Assistant Administrator in the Office of Diversion Control at the DEA. Janssen anticipates he will testify about DEA's interpretation and enforcement of, and practices related to, the Controlled Substances Act and its implementing regulations.
56. Carly Reisner
Chief Operating Officer, Association Management Center
Contact information: Association Management Center
8735 West Higgins Road, #300
Chicago, IL 60631

57. Mark Reynolds
Senior Director of Decision Support Services
Oklahoma Health Care Authority
Contact information: Counsel of record for the State of Oklahoma
58. Susan Rodgers
Executive Director and General Counsel
Oklahoma State Board of Dentistry
Contact information: Counsel of record for the State of Oklahoma
59. Julio Rojas
Psychologist
University of Oklahoma Medicine
Contact information: Counsel of record for the State of Oklahoma
60. Gary Schick
Physical medicine/rehabilitation physician
McBride Orthopedic Clinic
Contact information: Oklahoma City, OK
61. Carrie Slatton-Hodges
Deputy Commissioner
Oklahoma Department of Mental Health and Substance Abuse Services
Contact information: Counsel of record for the State of Oklahoma
62. Mark Stewart
Chief Agent
Oklahoma Bureau of Narcotics
Contact information: Counsel of record for the State of Oklahoma
63. Larry Sumner, M.D.
Contact information: Nate Young, Esq.
(918) 931-8328
Dr. Sumner is a physician whose records Dr. Jason Beaman reviewed as part of his analysis for this action. Janssen anticipates that Dr. Sumner will testify about the prescribing and use of prescription opioid medicines for chronic pain.
64. Travis Tate
Director of Pharmacy, Employees Group Insurance Division
Office of Management and Enterprise Services for the State of Oklahoma
Contact information: Counsel of record for the State of Oklahoma
65. Fred Tewell
Director of Marketing
Janssen
Contact information: Counsel of record for J&J and Janssen

66. Bruna Varalli-Claypool
Associate Professor
University of Oklahoma College of Medicine
Contact information: Counsel of record for the State of Oklahoma
67. Reji T. Varghese
Deputy Executive Director
Oklahoma State Board of Medical Licensure & Supervision
Contact information: Counsel of record for the State of Oklahoma
68. Patrick Verheyen
Global Health, Janssen Business Development
Janssen
Contact information: Counsel of record for J&J and Janssen
69. Robert Vogt
PMP Administrator
Appriss
Contact information: Counsel of record for the State of Oklahoma
70. Gary Vorsanger
Former Senior Medical Director, Medical Affairs
Janssen
Contact information: Counsel of record for J&J and Janssen
71. Kerri Wade
Pharmacy Operations Manager
Oklahoma Health Care Authority
Contact information: Counsel of record for the State of Oklahoma
72. Lynn Webster, MD
Vice President, Scientific Affairs
PRA Health Sciences
Contact information: John Robinson
Gordon & Rees Scully Mansukhani
95 Glastonbury Boulevard, Suite 206
Glastonbury, CT 06033
73. Darrell Weaver
State Senator for Oklahoma, District 24
Former Director
Oklahoma Bureau of Narcotics
Contact information: Counsel of record for the State of Oklahoma
74. Terri White
Commissioner
Oklahoma Dept. of Mental Health and Substance Abuse Services
Contact information: Counsel of record for the State of Oklahoma

75. Mark Woodward
Public Information and Education Officer and Legislative Liaison
Oklahoma Bureau of Narcotics
Contact information: Counsel of record for the State of Oklahoma
76. Kyle Wright
Staff Coordinator, Regulatory Division, Office of Diversion Control
Drug Enforcement Administration
Contact information: David Finkelstein
United States Department of Justice
David.M.Finkelstein@usdoj.gov
Mr. Wright is the former Staff Coordinator in the Regulatory Division in the Office of Diversion Control at the DEA. Janssen anticipates he will testify about DEA's interpretation and enforcement of, and practices related to, the Controlled Substances Act and its implementing regulations.
77. All current and former Janssen sales representatives noticed or subpoenaed for deposition in this action.
78. All expert witnesses that Janssen identified in its March 13, 2019 expert disclosures, except Drs. Douglas Posey and Martin Grabois.
79. All witnesses that Defendants Cephalon, Inc., Teva Pharmaceuticals USA, Inc., Watson Laboratories, Inc., Actavis LLC, and Actavis Pharma, Inc., f/k/a Watson Pharma Inc. identified in their March 1, 2019 Supplemental Disclosures and their March 13, 2019 Amended List of Expert Witnesses.

Dated: April 26, 2019

Respectfully submitted,

By: /s/ John H. Sparks

John H. Sparks, OBA No. 15661
Benjamin H. Odom, OBA No. 10917
Michael W. Ridgeway, OBA No. 15657
David L. Kinney, OBA No. 10875
ODOM, SPARKS & JONES, PLLC
Suite 140
HiPoint Office Building
2500 McGee Drive
Norman, OK 73072
Telephone: (405) 701-1863
Facsimile: (405) 310-5394
Email: odomb@odomsparks.com
Email: sparksj@odomsparks.com
Email: ridgewaym@odomsparks.com
Email: kinneyd@odomsparks.com

Larry D. Ottaway, OBA No. 6816
Amy Sherry Fischer, OBA No. 16651
Andrew Bowman, OBA No. 22071
Jordyn L. Cartmell, OBA No. 31043
FOLIART, HUFF, OTTAWAY & BOTTOM
12th Floor, 201 Robert S. Kerr Avenue
Oklahoma City, OK 73102
Telephone: (405) 232-4633
Facsimile: (405) 232-3462
Email: larryottaway@oklahomacounsel.com
Email: amyfischer@oklahomacounsel.com
Email: andrewbowman@oklahomacounsel.com
Email: jordyncartmell@oklahomacounsel.com

Of Counsel:

Charles C. Lifland
Wallace Moore Allan
Sabrina H. Strong
O'MELVENY & MYERS, LLP
400 S. Hope Street
Los Angeles, CA 90071
Telephone: (213) 430-6000
Facsimile: (213) 430-6407
Email: clifland@omm.com
Email: tallan@omm.com
Email: sstrong@omm.com

Stephen D. Brody
David Roberts
O'MELVENY & MYERS, LLP
1625 Eye Street NW
Washington, DC 20006
Telephone: (202) 383-5300
Facsimile: (202) 383-5414
Email: sbrody@omm.com
Email: droberts2@omm.com

**ATTORNEYS FOR DEFENDANTS
JANSSEN PHARMACEUTICALS, INC.,
JOHNSON & JOHNSON, JANSSEN
PHARMACEUTICA, INC. N/K/A JANSSEN
PHARMACEUTICALS, INC., AND
ORTHO-MCNEIL-JANSSEN
PHARMACEUTICALS, INC. N/K/A/
JANSSEN PHARMACEUTICALS, INC.**

CERTIFICATE OF MAILING

Pursuant to 12 O.S. § 2005(D), and by agreement of the parties, this is to certify on April 26, 2019, a true and correct copy of the above and foregoing has been served via electronic mail, to the following:

Mike Hunter
Attorney General for
The State of Oklahoma
Abby Dillsaver
Ethan Shaner
General Counsel to
The Attorney General
313 NE 21st
Oklahoma City, OK 73105
Telephone: (405)521-3921
Facsimile: (405) 521-6246
Email: mike.hunter@oag.ok.gov
Email: abby.dillsaver@oag.ok.gov
Email: ethan.shaner@oag.ok.gov

Michael Burrage
Reggie Whitten
J. Revell Parrish
WHITTEN BURRAGE
Suite 300
512 North Broadway Avenue
Oklahoma City, OK 73102
Telephone: (405) 516-7800
Facsimile: (405) 516-7859
Email: mburrage@whittenburragelaw.com
Email: rwhitten@whittenburragelaw.com
Email: rparrish@whittenburragelaw.com

Bradley Beckworth
Jeffrey Angelovich
Lloyd Nolan Duck, III
Andrew Pate
Lisa Baldwin
Brooke A. Churchman
Nathan Hall
NIX, PATTERSON, LLP
Suite 200
512 North Broadway Avenue
Oklahoma City, OK 73102

Telephone: (405) 516-7800
Facsimile: (405) 516-7859
Email: bbeckworth@nixlaw.com
Email: jangelovich@nixlaw.com
Email: tduck@nixlaw.com
Email: dpate@nixlaw.com
Email: lbaldwin@nixlaw.com
Email: bchurchman@nixlaw.com
Email: nhall@nixlaw.com

Robert Winn Cutler
Ross Leonoudakis
Cody Hill
NIX, PATTERSON, LLP
Suite B350
3600 North Capital of Texas Highway
Austin, TX 78746
Telephone: (512) 328-5333
Facsimile: (512) 328-5335
Email: winncutler@nixlaw.com
Email: rossl@nixlaw.com
Email: codyhill@nixlaw.com

Glenn Coffee
GLENN COFFEE & ASSOCIATES, PLLC
915 North Robinson Avenue
Oklahoma City, OK 73102
Telephone: (405) 601-1616
Email: gcoffee@glenncoffee.com

ATTORNEYS FOR PLAINTIFF

Sanford C. Coats
Joshua D. Burns
CROWE & DUNLEVY, PC
Suite 100
Braniff Building
324 North Robinson Avenue
Oklahoma City, OK 73102
Telephone: (405) 235-7700
Facsimile: (405) 272-5269
Email: sandy.coats@crowedunlevy.com
Email: joshua.burns@crowedunlevy.com

Of Counsel:

Sheila Birnbaum
Mark S. Cheffo
Hayden A. Coleman
Paul A. LaFata
Lindsay N. Zanello
Bert L. Wolff
Mara C. Cusker Gonzalez
Jenna C. Newmark
DECHERT, LLP
Three Bryant Park
1095 Avenue of Americas
New York, NY 10036-6797
Telephone: (212) 698-3500
Facsimile: (212) 698-3599
Email: sheila.birnbaum@dechert.com
Email: mark.cheffo@dechert.com
Email: hayden.coleman@dechert.com
Email: paul.lafata@dechert.com
Email: lindsay.zanello@dechert.com
Email: bert.wolff@dechert.com
Email: maracusker.gonzalez@dechert.com
Email: jenna.newmark@dechert.com

Benjamin F. McAnaney
Hope S. Freiwald
Will W. Sachse
Chelsea M. Nichols
Cory A. Ward
Meghan R. Kelly
Nicolas A. Novy
DECHERT, LLP
2929 Arch Street
Philadelphia, PA 19104
Telephone: (215) 994-4000
Facsimile: (215) 655-2043
Email: benjamin.mcananey@dechert.com
Email: hope.freiwald@dechert.com
Email: will.sachse@dechert.com
Email: chelsea.nichols@dechert.com
Email: cory.ward@dechert.com
Email: meghan.kelly@dechert.com
Email: nicolas.novy@dechert.com

Erik W. Snapp
DECHERT, LLP
Suite 3400
35 West Wacker Drive
Chicago, IL 60601
Telephone: (212)849-7000
Facsimile: (212) 849-7100
Email: erik.snapp@dechert.com

Jonathan S. Tam
Jae Hong Lee
DECHERT, LLP
16th Floor
One Bush Street
San Francisco, CA 94104
Telephone: (415) 262-4500
Facsimile: (415) 262-4555
Email: jonathan.tam@dechert.com
Email: jae.lee@dechert.com

William W. Oxley
DECHERT, LLP
Suite 4900
US Bank Tower
633 West 5th Street
Los Angeles, CA 90071
Telephone: (213) 808-5760
Facsimile: (213) 808-5760
Email: william.oxley@dechert.com

Lindsey B. Cohan
DECHERT, LLP
Suite 2010
300 West 6th Street
Austin, TX 78701-2961
Telephone: (212) 394-3000
Facsimile: (512) 394-3001
Email: lindsey.cohan@dechert.com

Britta E. Stanton
John D. Volney
John T. Cox, III
Eric W. Pinker
Jared D. Eisenberg

Jervonne D. Newsome
Elizabeth Yvonne Ryan
Andrea MeShonn Evans Brown
Ruben A. Garcia
Russell G. Herman
Samuel B. Hardy, IV
David S. Coale
Alan Dabdoub
LYNN PINKER COX & HURST, LLP
Suite 2700
2100 Ross Avenue
Dallas, TX 75201
Telephone: (214) 981-3800
Facsimile: (214) 981-3839
Email: bstanton@lynnllp.com
Email: jvolney@lynnllp.com
email: tcox@lynnllp.com
Email: epinker@lynnllp.com
Email: jeisenberg@lynnllp.com
Email: jnewsome@lynnllp.com
Email: eryan@lynnllp.com
Email: sbrown@lynnllp.com
Email: rgarcia@lynnllp.com
Email: rherman@lynnllp.com
Email: shardy@lynnllp.com
Email: dcoale@lynnllp.com
Email: adabdoub@lynnllp.com

Robert S. Hoff
WIGGIN & DANA, LLP
265 Church Street
New Haven, CT 06510
Telephone: (203) 498-4400
Facsimile: (203) 363-7676
Email: rhoff@wiggin.com

Michael T. Cole
NELSON MULLINS RILEY & SCARBOROUGH, LLP
Suite 600
151 Meeting Street
Charleston, SC 29401
Telephone: (843) 853-5200
Facsimile: (843) 722-8700
Email: mike.cole@nelsonmullins.com

**ATTORNEYS FOR DEFENDANTS PURDUE
PHARMA, LP,
PURDUE PHARMA, INC., AND THE
PURDUE FREDERICK
COMPANY, INC.**

Robert G. McCampbell
Travis V. Jett
Ashley E. Quinn
Nicholas V. Merkley
Leasa M. Stewart
GableGotwals
15th Floor
One Leadership Square
211 North Robinson
Oklahoma City, OK 73102-7255
Telephone: (405) 235-5567
Email: rmccampbell@gablelaw.com
Email: tjett@gablelaw.com
Email: aquinn@gablelaw.com
Email: nmerkley@gablelaw.com
Email: lstewart@gablelaw.com

Of Counsel:

Steven A. Reed
Rebecca J. Hillyer
Evan J. Jacobs
Morgan, Lewis & Bockius, LLP
1701 Market Street
Philadelphia, PA 19103-2321
Telephone: (215) 963-5000
Email: steven.reed@morganlewis.com
Email: rebecca.hillyer@morganlewis.com
Email: evan.jacobs@morganlewis.com

Harvey Bartle, IV
Mark A. Fiore
Morgan, Lewis & Bockius, LLP
502 Carnegie Center
Princeton, NJ 08540-6241
Telephone: (609) 919-6600
Email: harvey.bartle@morganlewis.com
Email: mark.fiore@morganlewis.com

Brian M. Ercole
Melissa M. Coates
Martha A. Leibell
Morgan, Lewis & Bockius, LLP
Suite 5300
200 South Biscayne Boulevard
Miami, FL 33131
Email: brian.ercole@morganlewis.com
Email: melissa.coates@morganlewis.com
Email: martha.leibell@morganlewis.com

**ATTORNEYS FOR DEFENDANTS
CEPHALON, INC., TEVA
PHARMACEUTICALS USA, INC., WATSON
LABORATORIES, INC.,
ACTAVIS, LLC, AND ACTAVIS PHARMA,
INC. F/K/A WATSON
PHARMA, INC.**

/s/ John H. Sparks

John H. Sparks, OBA No. 15661
Benjamin H. Odom, OBA No. 10917
Michael W. Ridgeway, OBA No. 15657
David L. Kinney, OBA No. 10875
ODOM, SPARKS & JONES, PLLC
Suite 140
HiPoint Office Building
2500 McGee Drive
Norman, OK 73072
Telephone: (405) 701-1863
Facsimile: (405) 310-5394
Email: odomb@odomsparks.com
Email: sparksj@odomsparks.com
Email: ridgewaym@odomsparks.com
Email: kinneyd@odomsparks.com

**ATTORNEYS FOR DEFENDANTS
JANSSEN PHARMACEUTICALS, INC.,
JOHNSON & JOHNSON, JANSSEN
PHARMACEUTICA, INC. N/K/A
JANSSEN PHARMACEUTICALS, INC.,
AND ORTHO-MCNEIL-JANSSEN
PHARMACEUTICALS, INC. N/K/A/
JANSSEN PHARMACEUTICALS, INC.**

EXHIBIT D

Code	Objection
AU	Not Authenticated (12 O.S. § 2901)
PR/AU	Public Record Not Certified or Insufficient Supporting Testimony (12 O.S. § 3005)
PO	Contrary to Prior Court order
CON	Confusing or Misleading (12 O.S. § 2403)
CU	Cumulative (12 O.S. § 2403)
INC	Incomplete; incomprehensible
IC	Improper Copy
H	Hearsay (12 O.S. § 2802)
INA	Contains inadmissible matter
2701	Contains Improper opinion of lay witness (12 O.S. § 2701)
LF	Lack of Foundation (12 O.S. § 2602)
ND	Not disclosed as required by a document request or mandatory disclosure
Scope	Outside the scope of deposition topics for which the witness is designated (12 O.S. §§ 3230, 3232)
P	Privileged (12 O.S. § 2501, et seq.)
MIL	Subject of a pending motion <i>in limine</i> (Teva MIL #; Janssen MIL #) See MIL Chart
R	Relevance, §§ 2401, 2402 (12 O.S. §§ 2401, 2402)
S	Speculation
SUM	Improper summary of underlying documents not made available
PRE	Unduly prejudicial-probative value outweighed by undue prejudice (12 O.S. § 2403)
V	Vague and ambiguous
	Nuisance Statute's Safe-harbor (50 O.S. § 4)
	First Amendment (U.S. Constitution, Amendment I)

Trial Exhibit No.	Trial Exhibit Descrip.	Production Beg Doc	Production End Doc	Deposition Exhibit No.	Objections	Authority
S-0001	Notice of Deposition			Fitzsimons 1	R; PRE; CU	12 O.S. 2401, 2402
S-0002	Composite Exhibit of Documents Reviewed by the Deponent			Fitzsimons 3	Nuisance Statute's Safe-harbor; AU; H; R; IC; LF; J-MIL 4; CU CON	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0003	Pages from the Tasmanian Alkaloids Website titled <i>Tasmanian Alkaloids Value Adding in Tasmania</i>			Fitzsimons 4	Nuisance Statute's Safe-harbor; AU; H; R; IC; LF; Scope; SUM; J-MIL 4; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0004	Document titled <i>Tasmanian Alkaloids Submission to the Legislative Counsel of Tasmania Select Committee Inquiry on the Tasmanian Poppy Industry</i>			Fitzsimons 5	Nuisance Statute's Safe-harbor; AU; H; R; LF; IC; Scope; J-MIL 4; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0005	Document titled <i>The Legislative Council select Committee on the Tasmanian Poppy Industry, a March 4, 2013 Transcript of a Town Hall Meeting</i>			Fitzsimons 6	First Amendment; Nuisance Statute's Safe-harbor; AU; H; R; LF; IC; Scope; J-MIL 4; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0006	Document titled <i>The Tasmanian Poppy Industry: A Case Study of the Application of Science and Technology by A.J. Fist</i>			Fitzsimons 7	AU; H; R; PRE; CON; CU; LF; IC; Scope; J-MIL 4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0007	March 9, 2016 News Article titled <i>SK Capital Partners Looks Set to Acquire Tasmania's Largest Poppy Processor</i>			Fitzsimons 8	Nuisance Statute's Safe-harbor; AU; H; R; LF; IC; Scope; J-MIL 4; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0008	Noramco Brochure Titled <i>Specialists in Controlled Substance Development and Manufacture</i>			Fitzsimons 9	Nuisance Statute's Safe-harbor; AU; H; R; LF; IC; Scope; J-MIL 4; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0009	July 19, 2014 New York Times Article titled <i>Shake-Up on Opium Island</i>			Fitzsimons 10	Nuisance Statute's Safe-harbor; AU; H; R; LF; IC; Scope; J-MIL 4; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0010	Johnson & Johnson Form 10-K (fiscal year ending 12/31/95)			Fitzsimons 2	Nuisance Statute's Safe-harbor; AU; H; R; LF; IC; Scope; J-MIL 4; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0011	2017 Annual Review of N. Sandusky	SANDUSKY000039	SANDUSKY000048	Sandusky 1	AU; H; R; LF; PRE; T-MIL 4; J-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0012	Screen Grabs of IC Plan	SANDUSKY000077	SANDUSKY000077	Sandusky 2	AU; H; R; LF; PRE; T-MIL 4; J-MIL 7; IC; INC; CON	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0013	Phoenix Snapshot for Charles Smith, D.O.	SANDUSKY000079	SANDUSKY000079	Sandusky 3	AU; H; R; LF; PRE; T-MIL 4; J-MIL 7; IC; INC; CON	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0014	Phoenix Home Page	SANDUSKY000080	SANDUSKY000080	Sandusky 4	AU; H; R; LF; PRE; T-MIL 4; J-MIL 7; IC; INC; CON	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0015	Screenshot of a meal for a physician	SANDUSKY000082	SANDUSKY000082	Sandusky 5	AU; H; R; LF; PRE; T-MIL 4; J-MIL 7; IC; INC; CON	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0016	Excerpt of Symproic Training Module	SANDUSKY000183	SANDUSKY000183	Sandusky 6	First Amendment; AU; H; R; LF; PRE; T-MIL 4; J-MIL 7; IC; INC; CON	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0017	2017 President's Club Rankings	SANDUSKY000212	SANDUSKY000212	Sandusky 7	AU; H; R; LF; PRE; T-MIL 4; J-MIL 7; IC; INC; CON	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0018	Weekly Prescriptions for Butrans and Hysingla	SANDUSKY000214	SANDUSKY000214	Sandusky 8	AU; H; R; LF; PRE; T-MIL 4; J-MIL 7; IC; INC; CON	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0019	Symproic Training Documents	SANDUSKY000216	SANDUSKY000216	Sandusky 9	First Amendment; AU; H; R; LF; PRE; T-MIL 4; J-MIL 7; IC; INC; CON	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0020	Pharma.learn.com Documents	SANDUSKY000312	SANDUSKY000312	Sandusky 10	AU; H; R; LF; PRE; T-MIL 4; J-MIL 7; IC; INC; CON	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0021	Slides from a Presentation	SANDUSKY000321	SANDUSKY000321	Sandusky 11	AU; H; R; LF; PRE; T-MIL 4; J-MIL 7; IC; INC; CON	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0022	Oklahoma District Roster	SANDUSKY000367	SANDUSKY000367	Sandusky 12	AU; H; R; LF; PRE; T-MIL 4; J-MIL 7; IC; INC; CON	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0023	iGallery Document Showing Weekly Scripts of Butrans	SANDUSKY000373	SANDUSKY000373	Sandusky 13	AU; H; R; LF; PRE; T-MIL 4; J-MIL 7; IC; INC; CON	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0024	Slides about Codeine Converting to Morphine	SANDUSKY000378	SANDUSKY000378	Sandusky 14	AU; H; R; LF; PRE; T-MIL 4; J-MIL 7; IC; INC; CON	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0025	CDC Guidelines Presentation	SAUNDUSKY000388	SANDUSKY000412	Sandusky 15	AU; H; R; LF; PRE; T-MIL 4; J-MIL 7; IC; INC; CON	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0026	President's Ranking including the standing of N. Sandusky	SANDUSKY000414	SANDUSKY000414	Sandusky 16	AU; H; R; LF; PRE; T-MIL 4; J-MIL 7; IC; INC; CON	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0027	Sandusky Self-Generated Report of Q4	SANDUSKY000416	SANDUSKY000416	Sandusky 17	AU; H; R; LF; PRE; T-MIL 4; J-MIL 7; IC; INC; CON	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0028	Weekly Tracking Report	SANDUSKY000455	SANDUSKY000455	Sandusky 18	AU; H; R; LF; PRE; T-MIL 4; J-MIL 7; IC; INC; CON	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0029	Medicaid Demand Opportunity Document	SANDUSKY000453	SANDUSKY000453	Sandusky 19	AU; H; R; LF; PRE; T-MIL 4; J-MIL 7; IC; INC; CON	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0030	Rankings Report	SANDUSKY000456	SANDUSKY000456	Sandusky 20	AU; H; R; LF; PRE; T-MIL 4; J-MIL 7; IC; INC; CON	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0031	Activites Undertook by Janssen to Ensure proper Patient Selection and Monitoring			Moskovitz 11	AU; LF; IC; SUM	
S-0032	Document Binder Produced by Janssen			Moskovitz 12	AU; H; R; PRE; CON; CU; LF; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0033	Depo Notice for 3230C5 Depo			Moskovitz 13	R; PRE; CU	
S-0034	8/9/01 Email String from Molly McDonald to Janssen Marketing Group Subj: OxyContin Tab Proper use v. Criminal Abuse - The Role of Oxy in Pain	JAN-MS-00654173		Moskovitz 14	AU; H; R; LF; PRE; INC	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0035	11/3/01 Executive Summary of Chronic Pain Scientific Advisory Board Meeting	JAN-MS-00782617		Moskovitz 15	AU; LF; R; PRE; H	
S-0036	Excerpt from 2002 Purdue Budget Plan	PDD1715031115	PDD1715031161	Moskovitz 16	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; IC; INC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0037	FDA Advisory Committee - Media Response Document	JAN-MS-00303831		Moskovitz 17	AU; LF; R; PRE; H	
S-0038	Warning Letter from FDA to Janssen	JAN-MS-00747492		Moskovitz 18	AU; LF; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0039	8/29/12 Email from Malcolm Monaghan to Ron Kuntz and Robyn Kohn subj: e-scan	JAN-MS-00453320			Moskovitz 19	AU; H; R; LF; PRE; CON; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0040	Resolution Urging States and Manufacturers	JAN-MS-00399104			Moskovitz 20	First Amendment; AU; H; R; LF; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0041	6/7/2007 "Leading the Fight Against Prescription Drug Abuse" Ortho-McNeil Powerpoint Slides	JAN-MS-00264550			Moskovitz 21	AU; H; R; LF; PRE; IC	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0042	Balance in Public Policy: Prescription Drug Monitoring Programs Issue Summary	JAN-MS-00929540			Moskovitz 22	First Amendment; AU; H; R; LF; PRE; J-MIL 2	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0043	MMWR CDC Guidelines for Prescribing Opioids for Chronic Pain - United States, 2016				Moskovitz 23	Nuisance Statute's Safe-harbor; Preemption; H; R; AU; LF; IC; Scope; T-MIL 8	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0044	2013 National Sales Meeting	WELLS000001	WELLS000089		Wells 21	H; AU; LF; R; PRE; T-MIL 4; J-MIL 7; IC; INC; CON; SUM	12 O.S. 2802
S-0045	Purdue Sales Class Journal	WELLS000104	WELLS000201		Wells 22	H; AU; LF; R; PRE; T-MIL 4; J-MIL 7; IC; INC; CON	12 O.S. 2802
S-0046	Oxycontin Exercise	WELLS000091	WELLS000094		Wells 23	H; AU; LF; R; PRE; T-MIL 4; J-MIL 7; IC; INC; CON	12 O.S. 2802
S-0047	CEB Document	WELLS000100	WELLS000101		Wells 24	AU; LF; R; PRE; T-MIL 4; J-MIL 7; IC; INC; CON; H	12 O.S. 2602, 12 O.S. 2901
S-0048	Topper's Club Information	WELLS000246	WELLS000255		Wells 25	H; AU; LF; R; PRE; T-MIL 4; J-MIL 7; IC; INC; CON	12 O.S. 2802
S-0049	President's Club Rankings	WELLS000218	WELLS000225		Wells 26	H; AU; LF; R; PRE; T-MIL 4; J-MIL 7; IC; INC; CON	12 O.S. 2802
S-0050	Yearly Review	WELLS000202	WELLS000255		Wells 27	AU; H; R; LF; PRE; T-MIL 4; J-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0051	Notice for 3230(C)(5) Witness				Hassler 1	H; R; PRE; CU	12 O.S. 2802
S-0052	"Making Pain Talk Painless" Report from the President's Commission on Combating Drug Addiction and the Opioid Crisis	TEVA_OK_00116233	TEVA_OK_00116236		Hassler 2	First Amendment; AU; H; R; LF; PRE; Scope; CON	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0053	United States Government's Memorandum for Entry of Plea and Sentencing	TEVA_OK_13597002			Hassler 3	AU; H; LF; PR/AU; Scope; R; PRE; 2701; T-MIL 1	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0054		TEVA_OK_13597140			Hassler 4	R; PRE; CON; CU; AU; H; PRE; LF; PR/AU; Scope; T-MIL 5	12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0055	Fentora Long Range Plan, 2010-2015	TEVA_OK_13597181		Hasler 5	R; PRE; CON; CU; AU; H; PRE; LF; Scope	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0056	Excel Spreadsheet	TEVA_OK_13597227		Hasler 6	R; PRE; CON; CU; AU; H; PRE; LF; Scops; INC; V	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0057	NYT Ad	PPLP004425066	PPLP004425066	Miller 1	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; Scope	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0058	Pain Killer Scripts per Person Map	PPLP004425067		Miller 2	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; V; INC; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0059	OK OD Rates Chart	PPLP004425068		Miller 3	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; V; INC; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0060	Journal Citation	PPLP004425069	PPLP004425069	Miller 3A	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; V; INC; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0061	OK Opioids Pain Reliever Deaths	PPLP004425070		Miller 4	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; V; T-MIL 1	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0062	Presidents Commission on Combating the Opioids Crisis	PPLP004425071	PPLP004425208	Miller 5	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; T-MIL 1, PR/AU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0063	Preventing & Treating Narcotic Addiction	PPLP004425209	PPLP004425211	Miller 6	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0064	Addiction Potential of Oxycodone	PPLP004425212	PPLP004425215	Miller 7	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0065	Goldenheim Plea Agrmt	PPLP004425216	PPLP004425222	Miller 8	R; PRE; CON; CU; AU; H; PRE; LF; T-MIL 4; J-MIL 7; PR/AU; T-MIL 5, H	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0066	Friedman Plea Agrmt	PPLP004425223	PPLP004425229	Miller 9	R; PRE; CON; CU; AU; H; PRE; LF; T-MIL 4; J-MIL 7; PR/AU; T-MIL 5, H	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0067	Urdeil Plea Agrmt	PPLP004425230	PPLP004425236	Miller 10	R; PRE; CON; CU; AU; H; PRE; LF; T-MIL 4; J-MIL 7; PR/AU; T-MIL 5, H	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0068	USA v. Purdue Frederick Promotion and Marketing of Oxy, Commercial Triumph, Public Health Tragedy	PPLP004425237	PPLP004425252	Miller 11	R; PRE; CON; CU; AU; H; PRE; LF; T- MIL 4; J-MIL 7; PR/AU; T-MIL 5, H	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0069	Chronic Opioid Therapy for Non- Malignant Pain	PPLP004425253	PPLP004425259	Miller 12	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0070	Porter & Jick Article	PPLP004425260	PPLP004425263	Miller 13	Discovery Violations; AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0071	Myths About Opioids Article	PPLP004425264	PPLP004425264	Miller 14	First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0072	1980 Letter on The Risk of Opioids	POK000205061	PPLP004425285	Miller 15	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0073	2001 Budget Plan Excerpt	PPLP004425294	PPLP004425302	Miller 16	Nuisance Statute's Safe-harbor; Preemption; AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0074	Purdue Pharma Applauds Ethical Marketing Code by PhRMA	POK000241396	PPLP004425305	Miller 17	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0075	CDC Prescribing Guidelines	PPLP004425349	PPLP004425358	Miller 18	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; SUM	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0076	Purdue Action	POK000273432	PPLP004425349	Miller 19	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0077	GAO Report	PDD1715030725	PPLP004425349	Miller 20	H; R; PRE; CU	12 O.S. 2401, 2402; 12 O.S. 2802
S-0078	Lisa Miller Depo Notice NYT			Miller 21	H; R; PRE; CU	12 O.S. 2401, 2402; 12 O.S. 2802
S-0079	Lisa Miller Depo Notice Abatement			Miller 22	R; PRE; CON; CU; AU; H; PRE; LF; T- MIL 4; J-MIL 7; INC; IC; V	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0080	"Abuse/Diversion"			Miller 23		
S-0081				Miller 24		

S-0082	Increase in Unintentional Medication Overdoses	PPLP004425059	PPLP004425065	Miller 25	Nuisance Statute's Safe-harbor; Preemption; AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0083	Purdue Pro Forma Depo Notice	PPLP004422584	PPLP004422590	Darragh 1	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0084	Purdue Combined Financial Stmtms 16-17	PPLP004422591	PPLP004422649	Darragh 2	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0085	Purdue Spplie Response to Rog 2	PPLP004422650	PPLP004422656	Darragh 3	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; SUM	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0086	Response to Request for Corporate Structure Info.	PPLP004422657	PPLP004422663	Darragh 4	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; SUM	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0087	Purdue Balance Sheets	POK003284969		Darragh 5	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; SUM; INC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0088	Handwritten Financial Structure Diagram	PPLP004422667	PPLP004422667	Darragh 6	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; IC; INC; V	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0089	Purdue Combined Financial Stmtms 14-15	POK003285665		Darragh 7	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; SUM	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0090	Purdue Combined Financial Stmtms 04-05	POK003285231		Darragh 8	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; SUM	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0091	Craig Landau Appointed CEO Article	PPLP004422774	PPLP004422774	Darragh 9	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0092	Purdue Combined Financial Stmtms 06-07	POK003285326		Darragh 10	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; SUM	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0093	Purdue Combined Financial Stmtms 10-11	POK003285484		Darragh 11	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; SUM	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0094	Printout of Keith Auer LinkedIn Profile			Auer 1	AU; H; LF; R; PRE; IC; INC; CON; V	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0095	Training Progress Report	JANS-MS-00063716		Auer 2	AU; H; LF; R; PRE; IC; CON	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0096	Training Progress Report	JAN-MS-00063716		Auer 3	AU; H; LF; R; PRE; IC; CON; INC	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0097	Weekly Status Report	JAN-MS-00063716		Auer 4	AU; H; LF; R; PRE; INC; CON	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0098	Advisor Class Feedback, Keith Auer	JAN-MS-00063742		Auer 5	AU; H; LF; R; PRE; IC; INC; CON	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0099	Training Progress Report	JAN-MS-00062498		Guthrie 1	AU; H; LF; R; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0100	E-mail, 1/12/10	JAN-MS-00360251		Guthrie 2	R; PRE; CON; CU; AU; H; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0101	Q4 Targets Hyperfrequency Action Plan	JAN-MS-00358227		Guthrie 3	R; PRE; CON; CU; AU; H; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0102	IM Retail PNYM \$25 Card and 10 Free Pill Voucher Allocation Program	JAN-MS-02471270		Guthrie 4	AU; H; LF; R; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0103	Nucynta 2011 Business Plan, July 27, 2010, Draft Only	JAN-MS-00132333	JAN-MS-00132386	Guthrie 5	AU; LF; R; PRE	
S-0104	Deposition Subpoena Duces Tecum			Diesselhorst 1	R; PRE; CU	
S-0105	2/9/11 Janssen Employee Roster	JAN-MS-00371179		Diesselhorst 2	R; PRE; CON; CU; AU; H; PRE; LF; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0106	PriCara Pain 2010 Incentive Compensation & Recognition Plan Right Now Nucynta Contest Slides	JAN-MS-00862041		Diesselhorst 3	Nuisance Statute's Safe-harbor; Preemption; R; PRE; CON; CU; AU; H; R; PRE; LF; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0107	8/3/09 Email from Frank Demiro to Jean Nycz, Subject: FW: Program Update Needed	JAN-MS-00358879		Diesselhorst 4	AU; LF; R; PRE	
S-0108	Spreadsheet Attached to the 8/3/09 Email from Frank Demiro to Jean Nycz, Subject: FW: Program Update Needed	JAN-MS-00358880		Diesselhorst 5	AU; LF; R; PRE; INC	12 O.S. 2602, 12 O.S. 2901
S-0109	Janssen Call Note Spreadsheet	JAN-OK-00000001	JAN-OK00000004	Diesselhorst 6	AU; LF; R; PRE J-MIL 16; V; INC	12 O.S. 2602, 12 O.S. 2901
S-0110	7/6/09 Email from Michelle Mason to Paula Ohnemus, Subject: Success	JAN-MS-00813092	JAN-MS-00813093	Diesselhorst 7	AU; H; LF; R; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0111	12/18/08 Tapentadol Chronic Pain Management Message Platform Slides	JAN-MS-00298408		Diesselhorst 8	AU; LF; R; PRE; IC; CU	

S-0112	"The Promotion and Marketing of OxyContin: Commercial Triumph, Public Health Tragedy" by Art Van Zee, M.D.				Diesselhorst 9	AU; H; R; LF; PRE; IC; S	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0113	CDC Guidelines for Prescribing Opioids for Chronic Pain - United States, 2016				Diesselhorst 10	AU; H; LF; R; PRE; IC	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0114	Deposition Subpoena Duces Tecum Card and 10 free-fill Voucher Allocation Program Spreadsheet (portion)				McClure 1	AU; H; R; PRE; CU	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0115		JAN-MS-00026898			McClure 2	AU; H; LF; R; PRE; CU; INC; IC	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0116	Dr. Dennis Roberts Spreadsheet	JAN-OK-00000003, JAN-OK-00000004			McClure 3	AU; H; LF; R; PRE; INC; IC; CON	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0117	PriCara Pain Nucynta Contest	JAN-MS-00862041			McClure 4	Nuisance Statute's Safe-harbor; Preemption; AU; H; R; LF; PRE; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0118	Email chain dated 10-2011 between F. Demiro, M. Tascon, E. Anderson, R. Marshall	JAN-MS-00837521		JAN-MS-008373574	McClure 5	Nuisance Statute's Safe-harbor; Preemption; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0119	Email dated 10-13-2010 from S. Viger to Sales Force	JAN-MS-00864438		JAN-MS-00864440	McClure 6	AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0120	Launch Incentive Plan and Contest	JAN-MS-259761			Everly 1	AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0121	Tapentadol Professional Education Platform	JAN-MS-00298408			Everly 2	AU; H; CON; CU	
S-0122	2012 Incentive Compensation and Recognition Plan (89006-89037)	JAN-MS-0008906		JAN-MS-00089037	Howard 1	AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0123	Order Accepting Voluntary Submittal to Jurisdiction				Howard 2	Judicial Estoppel; R; PRE; CON; CU; H; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2802
S-0124	Spreadsheet Re: Dennis Roberts	JAN-OK-00000003, JAN-OK-00000004			Howard 3	Judicial Estoppel; R; PRE; CON; CU; AU; H; LF; R; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0125	Training Progress Report	JAN-MS-00061231			Howard 4	AU; H; LF; R; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0126	Training Progress Report	JAN-MS-00060670			Howard 5	AU; H; LF; R; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0127	Deposition Subpoena Duces Tecum				Lockhart 1	R; PRE; CU	

S-0128	Top Performers - March 2010	JAN-MS-00857316		Lockhart 2	AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0129	Sales Training, Janssen	JAN-MS-00060569	JAN-MS-00060590	Lockhart 3	AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0130	Field Communications, PAIN News	JAN-MS-00937641	JAN-MS-00937646	Lockhart 4	AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0131	Game On, Janssen	JAN-MS-00089730	JAN-MS-00089895	Lockhart 5	AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0132	Program Rules & Eligibility Duragesic, "Defend & Grow Initiative"	JAN-MS-00369998		Lockhart 6	Nuisance Statute's Safe-harbor; Preemption; R; PRE; CON; CU; AU; H; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0133	Defend and Grow July - December	JAN-MS-00370020		Lockhart 7	Nuisance Statute's Safe-harbor; Preemption; R; PRE; CON; CU; AU; H; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0134	Call Notes (portion)	JAN-OK-00000001	JAN-OK00000004	Lockhart 8	AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0135	Retail Sales Training 101 Preparation, 42 pages	JAN-MS-00064181		Lockhart 9	AU	12 O.S. 2602, 12 O.S. 2901
S-0136	Information, State of OK v Regan Nichols, CF-2017-3954, Oklahoma County			Lockhart 10	PRE; CON; CU; AU; LF; H	12 O.S. 2403
S-0137	Former Patient of Midwest City Doctor Charged with Murder Says Arrest a "relief"			Lockhart 11	Judicial Estoppel; R; PRE; CON; CU; AU; H; PRE; LF; R; T-MIL 7	12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0138	Information Regarding OxyContin, Upcoming Poster Presentation at American Pain Society Conference	POK003275185	POK003275186	Mason 1	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; J-MIL 12	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0139	"I'd Like to Work on My Closing Techniques"	POK003274885		Mason 2	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0140	Update on Ordering Experience Programs & Shipping	POK003276909	POK003276933	Mason 3	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0141	Partners Against Pain	POK000404743	POK000404770	Mason 4	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0142	Email from Eric Wayman to Cullen Bryant, Subject: Hysingla Record	BRYANT000001		Bryant 1	AU; H; R; LF; PRE; T-MIL 4; J-MIL 7; IC; INC; CON; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0143	Email from Eric Wayman to Cullen Bryant, Subject: Hysingla Record	BRYANT000004		Bryant 2	H; AU; LF; R; PRE; T-MIL 4; J-MIL 7; IC; INC; CON; V	12 O.S. 2802
S-0144	Email from Eric Wayman to Cullen Bryant, Subject: Butrans/Hysingla Record	BRYANT000005		Bryant 3	H; AU; LF; R; PRE; T-MIL 4; J-MIL 7; IC; INC; CON; V	12 O.S. 2802
S-0145	Purdue Awards Summary Report for Cullen Bryant	BRYANT000006	BRYANT000008	Bryant 4	H; AU; LF; R; PRE; T-MIL 4; J-MIL 7; IC; INC; CON; V	12 O.S. 2802
S-0146	Email from David McIntyre to Cullen Bryant, Subject: 2017 President's Club	BRYANT000011		Bryant 5	H; AU; LF; R; PRE; T-MIL 4; J-MIL 7; IC; INC; CON; V	12 O.S. 2802
S-0147	Purdue Marketing Memo from the Marketing Department to the Purdue Sales Force	POK003276909		Bryant 6	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0148	SDT 8/23/18	PPLP004423480	PPLP004423486	Gardiner 1	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0149	Linked In Profile	PPLP004423487	PPLP004423488	Gardiner 2	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 8, IC; INC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0150	Opioid Knockoff article	PPLP004423489	PPLP004423490	Gardiner 3	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 8, IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0151	OxyContin maker Purdue to stop promotion cuts half of sales staff - article	PPLP004423491	PPLP004423492	Gardiner 4	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 8, IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0152	Amie Gardiner Sales Notes	PPLP004423493	PPLP004423510	Gardiner 5	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 8, IC; INC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0153	Amie Gardiner Call Notes	PPLP004423511	PPLP004423523	Gardiner 6	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 8, IC; INC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0154	Sentancing for Regan Nichols	PPLP004423524	PPLP004423528	Gardiner 7	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; PR/AU; T-MIL 5, H	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0155	Amie Gardiner 2014 Call Notes	PPLP004423529	PPLP004423572	Gardiner 8	Nuisance Statute's Safe-harbor; Preemption; AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 8, IC; INC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0156	Russ Gasdia Sales Notes to Purdue Sales Force	POK003278581		Gardiner 9	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 8, IC; J-MIL 12, H	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0157	Purdue Third Quarter Incentive Program	POK003277934	Gardiner 10	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0158	Third Quarter 2014 Incentive Program	POK003276373	Gardiner 11	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0159	PROVIDING RELIEF PREVENTING ABUSE BROCHURE	POK000404784	Gardiner 12	AU; H; R; PRE; CON; CU; LF; T-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0160	Purdue Marketing Tips Telemarketing Program	POK003278992	Gardiner 13	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0161	Purdue Sales Bulletin	POK003277024	Gardiner 14	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0162	iding Patients Consisten with Recent Label Changes	POK003276180	Gardiner 15	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0163	OxyContin Xponent Ranking Memo	POK003277094	Gardiner 16	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0164	2013 year in Review Memo	POK003276340	Gardiner 17	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0165	Revised Standard Operating Policies	POK003279032-61	Wolfinbarger A	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0166	Hysingla Package Insert		Wolfinbarger B	AU; H; R; PRE; CON; CU; LF; T-MIL 7; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0167	Sales Training, "Promotional Messaging Issues"	POK003279103-8	Wolfinbarger C	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0168	Purdue Sales Document to District Managers	POK003276766-78	Wolfinbarger D	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0169	Salesforce Gifts and Meals Update	POK003276782-94	Wolfinbarger E	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0170	Pharmaceutical Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries Article				Wolfinbarger F	H; AU; LF; R; PRE; T-MIL 4; J-MIL 7; IC	12 O.S. 2802
S-0171	"Growth for Hysingla ER"	POK003276892-3			Wolfinbarger G	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; J-MIL 12	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0172	Butrans Scripts and Weekly Rankings	Wolfinbarger000001-28			Wolfinbarger H	H; R; AU; LF; PRE; T-MIL 4; J-MIL 7; J-MIL 12; IC; INC; CON; V	12 O.S. 2401, 2402; 12 O.S. 2802
S-0173	New York Times Ad				Previously Marked Ex 1	AU; H; R; LF; PRE; T-MIL 4; J-MIL 7; IC	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0174	GAO Report	POK000273432-94			Previously Marked Ex 2	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0175	Presidents Commission of Opioid Crisis				Previously Marked Ex 3	R; PRE; CON; CU; AU; LF; PR/AU; 2701; T-MIL 1	12 O.S. 2401, 2402; 12 O.S. 2403
S-0176	"Making Pain Talk Painless"	TEVA OK 00116233			Vaughn 2	AU; H; LF; R; PRE; Scope; CON	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0177	Map of Pain Killer Prescriptions	PPLP004425067			Vaughn 7	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; V; INC; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0178	Unintentional Overdose Death Rates Chart	PPLP004425068			Vaughn 8	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; V; INC; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0179	Number of Drug Overdose deaths involving opioid pain relievers and other drugs, OK residents	PPLP004425070			Vaughn 9	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; V; INC; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0180	Government's Memo for Plea and Sentencing for Cephalon	TEVA_OK_13597140			Vaughn 10	H; AU; LF; PR/AU; T-MIL 5; R; PRE; PO	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0181	ACTIQ Package Insert				Vaughn 11	AU; H; LF; IC; T-MIL 8	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0182	Cephalon Pharma Business Unit	TEVA 65903			Vaughn 12	AU; H; LF; IC; R; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0183	Region 65 Segmentation reports	TEVA OK 00944096			Vaughn 13	AU; H; LF; R; PRE; S; J-MIL 12	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0184	Call Logs	TEVA OK 01533990			Vaughn 14	AU; H; LF; R; PRE; CU; IC; INC; V; CON; J-MIL 16	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0185	The President's Commission on Combating Drug Addiction and the Opioid Crisis				Prev Marked 3	R; PRE; CON; CU; AU; LF; PR/AU; 2701; T-MIL 1	12 O.S. 2401, 2402; 12 O.S. 2403
S-0186	Map, Some states Have More Painkiller Prescriptions Per Person Than Others	PPLP004425067			Prev Marked 7	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; V; INC; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0187	Graph, Unintentional medication-related overdose death rates and total sales of prescription opioids by year, Oklahoma, 1994-2006	PPLP004425068			Prev Marked 8	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; V; INC; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0188	Number of Drug Overdose deaths involving opioid pain relievers and other drugs. Oklahoma residents, 2004-2012	PPLP004425070			Prev Marked 9	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; V; INC; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0189	USA vs. Cephalon, Government's Memorandum for Entry of Plea and Sentencing	TEVA_OK_13597140			Prev Marked 10	R; PRE; CON; CU; AU; LF; PR/AU; T-MIL 5; H	12 O.S. 2401, 2402; 12 O.S. 2403
S-0190	Fentora - Prescribing Information				Costa 15	AU; LF; H; IC; T-MIL 8	12 O.S. 2602, 12 O.S. 2901
S-0191	Field Contact Report	TEVA_OK_0054765-534768			Costa 16	R; AU; LF; H; S; V	12 O.S. 2401, 2402
S-0192	10/20/18 Email	TEVA_OK_01069460-1069469			Costa 17	R; AU; LF; H; P; PRE; S	12 O.S. 2401, 2402
S-0193	8/20/12 Email	TEVA_OK_01072338-1072340			Costa 18	AU; H; R; LF; PRE; S	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0194	8/16/13 Email	TEVA_OK_00614133			Costa 19	AU; H; R; LF; PRE; S	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0195	6/14/13 Email	TEVA_OK_0112840-112841			Costa 20	AU; H; R; LF; PRE; S; INC	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0196	6/15/09 Email	TEVA_OK_01081782			Costa 21	AU; H; R; LF; PRE; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0197	First Start Meeting	TEVA_OK_00008185			Costa 22	AU; H; R; LF; PRE; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0198	Fentora Annotated Sales Aid	TEVA_OK_01081729	TEVA_OK_01081744		Costa 23	AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0199	Regional Sales Meeting	TEVA_OK_00008586		Costa 24	AU; H; R; LF; PRE; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0200	Fast Start - Denver, CO	TEVA_OK_00008727		Costa 25	AU; H; R; LF; PRE; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0201	Little Red Book of Selling	TEVA_OK_13595652		Costa 26	AU; H; R; LF; PRE; CU; IC; INC	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0202	Imagine the Possibilities	TEVA_OK_13595653		Costa 27	AU; H; R; LF; PRE; IC; S	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0203	Actiq, a Pain Primer	TEVA_OK_00116240-116250		Costa 28	AU; R; LF; H; PRE; CU; IC; S	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901
S-0204	Call Notes	TEVA_OK_13595693		Costa 29	AU; H; R; LF; PRE; CU; IC; INC; V; CON; J-MIL 16	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0205	Call Notes - Jenkins	TEVA_OK_13595703		Costa 30	AU; H; R; LF; PRE; CU; IC; INC; V; CON; J-MIL 16	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0206	Call Notes	TEVA_OK_13595704		Costa 31	AU; H; R; LF; PRE; CU; IC; INC; V; CON; J-MIL 16	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0207	Call Notes	TEVA_OK_01850004		Costa 32	AU; H; R; LF; PRE; CU; IC; INC; V; CON; J-MIL 16	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0208	Email President's Commission on Combating Drug Addiction and the Opioids Crisis	TEVA_OK_01081468-1081469		Costa 33	R; PRE; CON; CU; AU; H; PRE; LF; S	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0209	Oklahoma's Commission on Opioid Abuse			Samples 1	H; R; PRE; CON; CU; AU; LF; PR/AU; 2701; T-MIL 1	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802
S-0210	CDC Guidelines for Prescribing Opioids for Chronic Pain			Samples 2	H; PRE; CON; CU; AU; LF; PR/AU; R; 2701; T-MIL 1	12 O.S. 2403; 12 O.S. 2802
S-0211	Sales Training Slide Deck for Nucynta and Nucynta ER (Confidential)	JAN-MS-000060569		Samples 3	AU; H; LF; R; PRE; 2701; T-MIL 1	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0212				Samples 4	AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0213	"Workshop 6 REV IT UP! Facilitator's Guide. Be the revolution" (Confidential)	JAN-MS-00128533	JAN-MS-00128609	Samples 5	Nuisance Statute's Safe-harbor; Preemption; R; PRE; CON; CU; AU; H; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0214	Package Insert			Samples 6	H; AU; LF; IC; T-MIL 8	12 O.S. 2802
S-0215	2012 Incentive Compensation and Recognition Plan	JAN-MS000089006	JAN-MS-00089037	Samples 7	AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0216	Training Progress Report (Confidential)	JAN-MS-00060670-		Samples 8	H	12 O.S. 2802
S-0217	Advisor Class Feedback (Confidential)	JAN-MS-00060695		Samples 9	AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0218	Subpoena			Diesselhorst 1	R; PRE; CU	
S-0219	LinkedIn profile of R. Diesselhorst			Diesselhorst 2	H; AU; LF; R; PRE; IC; INC	12 O.S. 2802
S-0220	PriCara Newsletter (Confidential)	JAN-MS-00500183	JAN-MS-00500188	Diesselhorst 3	Nuisance Statute's Safe-harbor; Preemption; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0221	2009 Incentive Compensation and Recognition Plan - Pricara Pain Representative - Q3 Update	JAN-MS-00589612	JAN-MS-00589622	Diesselhorst 4	AU; H; PRE	
S-0222	2006 Goals and Objectives for PriCara and Ortho-McNeil (Confidential)	JAN-MS-02015816	JAN-MS-02015822	Diesselhorst 5	PRE; CON; CU; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0223	"Tapentadol, NEO-Pathways" (Confidential)	JAN-MS-00476031	JAN-MS-00476033	Diesselhorst 6	AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0224	Pain Therapeutic Area Strategy dated August 25, 2004 (Confidential)	JAN-MS-00778382		Diesselhorst 7	Inadmissible Character Evidence; R; PRE; CON; CU; AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0225	2008 Objectives PowerPoint (Confidential)	JAN-MS-00876172		Diesselhorst 8	Inadmissible Character Evidence; R; PRE; CON; CU; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0226	Deposition Transcript of Drue Diesselhorst			Diesselhorst 9	AU; H; R; LF; PRE; IC	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0227	LinkedIn profile			Tilley 1	H; AU; LF; R; PRE; IC; INC	12 O.S. 2802
S-0228	PriCara Pain Representative - Q3 Update	JAN-MS-00589612-589622		Tilley 2	AU	12 O.S. 2602, 12 O.S. 2901
S-0229	Ultram C IV Label			Tilley 3	AU; H; LF; IC; T-MIL 8	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0230	PriCara Informaiton Exchange,	JAN-MS-00500183-500188		Tilley 4	AU	12 O.S. 2602, 12 O.S. 2901

S-0231	Pr/Cara Non-Branded Promotion, PowerPoint	JAN-MS-00442058		Tilley 5	PRE; AU; H; CON	
S-0232	Pr/Cara Inter-Office Memorandum	JAN-MS-00360537	JAN-MS-00360538	Tilley 6	AU	12 O.S. 2602, 12 O.S. 2901
S-0233	Tapentadol Neo-Pathways, Heading in new directions in pain management	JAN-MS-00476031-476033		Tilley 7	AU	12 O.S. 2602, 12 O.S. 2901
S-0234	Duragesic Disease Modeling Workshop for Johnson & Johnson, Discussion Document	JAN-MS-02339227		Tilley 8	AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0235	Ultram ER Label			Tilley 9	AU; H; LF; IC; T-MIL 8	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0236	Notice			Hassler 34	H; R; PRE; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0237	2005 Spreadsheet	TEVA_OK_1062582		Hassler 35	R; PRE; CON; CU; AU; H; PRE; LF; IC; INC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0238	2006 Spreadsheet	TEVA_OK_1517025		Hassler 36	R; PRE; CON; CU; AU; H; PRE; LF; IC; INC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0239	2007 Spreadsheet	TEVA_OK_537212		Hassler 37	R; PRE; CON; CU; AU; H; PRE; LF; IC; INC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0240	2008 Spreadsheet	TEVA_OK_1009606		Hassler 38	R; PRE; CON; CU; AU; H; PRE; LF; IC; INC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0241	2012-2013 Spreadsheet	APS-MDL00000001	APS-MDL00000047	Hassler 39	First Amendment; AU; H; LF; R; PRE; CU; IC; SUM; V; CON; Scope	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0242	Email from Richardson	TEVA_OK_01098122		Hassler 40	First Amendment; R; PRE; CON; CU; AU; H; PRE; LF; R; V; S	12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0243	Sales Training Overview	TEVA_OK_000061905		Hassler 41	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; S	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0244	Pain Care Forum Document	WIS_pppSG_002248		Hassler 42	First Amendment; R; PRE; CON; CU; AU; H; PRE; LF; R; IC; S; J-MIL 3; Scope	12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0245	Distribution and Supply Agreement between Purdue and Teva (draft)	TEVA_OK_00898621		Hassler 43	AU; H; R; LF; PRE; CU; IC; SUM; V; CON; Scope; PO	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0246	The Pain Care Forum Need	JAN-MS00934869		Ponder 1	First Amendment; AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0247	Pain Care Forum 2010 Meeting Schedule	NPRO0001TPP000002418		Ponder 2	First Amendment; AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0248	Pain Care Forum Agenda	JAN-MS-00614872		Ponder 3	First Amendment; AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0249	Effect of FSMB Model Guidelines	NPRO0001TPP000004905		Ponder 4	First Amendment; AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0250	Deadline for Pain Care Forum Priorities	NPRO0001TPP000005468		Ponder 5	First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0251	Responsible Opioid Prescribing (portion)			Ponder 6	First Amendment; AU; H; LF; R; PRE; IC; CON; V	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0252	Pain Care Forum Legislative Working Group	NPRO-0001TPP000004892		Ponder 7	First Amendment; AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0253	The Epidemic of Pain in America (short)			Ponder 8	First Amendment; AU; H; LF; R; PRE; PR/AU; IC; S	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0254	J&J Request for Proposal			Ponder 9	First Amendment; AU; H; LF; R; PRE; PR/AU; IC; S; CON; INC; SUM	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0255	Purpose of Travel Memo	JAN-MS-00411972		Ponder 10	First Amendment; AU; H	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0256	Janssen Sponsorship	JAN-MS-00400194		Ponder 11	First Amendment; AU; H; R	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0257	August 10, 2010 Letter	JAN-MS-00411692		Ponder 12	First Amendment; AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0258	Marketing Sponsorship Agreement	JAN-MS-00916010		Ponder 13	First Amendment; AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0259	Lunch Briefing Invitation	NPRO0001TPP000001837		Ponder 14	First Amendment; AU; H	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0260	Howard Udell Email	PPLP004321111		Ponder 15	First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL 7; J-MIL 4; IC; S; V	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0261	Groups Currently Partnering with Janssen	JAN-MS-00855080		Ponder 16	First Amendment; AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0262	National Advocacy Approach	JAN-MS-00264395		Ponder 17	First Amendment; AU; H	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0263	Advocacy, Policy, Quality Activities	JAN-MS-00409779		Ponder 18	First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0264	Communications and External Affairs Committee August 14th Minutes/Action Items	PPLP004273866	PPLP004273869	Ponder 19	First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL 7; J-MIL 4; IC; S; V	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0265	2013 National Advocacy Business Planning	JAN-MS-00405372		Ponder 20	First Amendment; Nuisance Statute's Safe-harbor; Preemption; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0266	Pain Policy Overview March 11, 2008	JAN-MS-00442778		Ponder 21	First Amendment; Nuisance Statute's Safe-harbor; Preemption; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0267	SGA Update	JAN-MS-02017234		Ponder 22	First Amendment; R; PRE; CON; CU; AU; H; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0268	Gary Vorsanger Email February 19, 2008	JAN-MS-02149093		Ponder 23	R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0269	Gary Vorsanger Email February 21, 2018	JAN-MS-02149085		Ponder 24	First Amendment; R; PRE; CON; CU; AU; H; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0270	Follow The Money.org - Johnson & Johnson			Ponder 25	First Amendment; AU; H; LF; R; PRE; IC; S; CON; V; INC	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0271	Amended Deposition Subpoena Ducas Tecum			Flanary 1	R; PRE; CU	
S-0272	Jason Flanary's Resume			Flanary 2	AU; H; LF; R; PRE; IC; INC	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0273	Email String Re: Updated: VitalSigns Plus Mobile	JAN-MS-01122451	JAN-MS-01122452	Flanary 3	AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0274	1-31-12 Email from Darlene Bunca Re: National Nucynta Data with Northeast Region Recognition	JAN-MS-00665009		Flanary 4	AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0275	7-27-10 Nucynta 2011 Business Plan (Draft Only)	JAN-MS-00132333	JAN-MS-00132386	Flanary 5	J-MIL #4; PRE; R; CON; AU; H	
S-0276	Johnson & Johnson Request for Proposal			Flanary 6	R; PRE; CON; CU; AU; H; PRE; LF; PR/AU; IC; S; INC; SUM	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0277	Nucynta Drug Label			Flanary 7	AU; H; R; LF; IC; T-MIL 8	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0278	Email String re: Nucynta ER Formulary Announcement	JAN-MS-02362329	JAN-MS-02362330	Flanary 8	AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0279	PowerPoint Presentation - Account Planning Workshop	JAN-OK-00137622		Flanary 9	AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0280	Institutional Specialist Competency Model	JAN-MS-0088964	JAN-MS-00089005	Flanary 10	AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0281	PowerPoint "Game On"	JAN-MS-00089730	JAN-MS-00089895	Flanary 11	AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0282	PowerPoint "Attitude - Reach New Heights"	JAN-MS-00089006	JAN-MS-00089037	Flanary 12	PRE; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0283	PowerPoint Presentation "2009 Incentive Compensation and Recognition Plan"	JAN-MS-00259761		Flanary 13	R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0284	Video Clips			Cambra 1	AU; H; R; PRE; CON; CU; LF; T-MIL 7; J-MIL 4; V	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0285	"Board Oks Narcotic Use for Chronic Pain," Article from the Raleigh News & Observer			Cambra 2	R; PRE; CON; CU; H; PRE; AU; LF; IC; V	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802
S-0286	"I Got My Life Back" Transcript	PKY180145193	PKY180145236	Cambra 3	Judicial Estoppel; Nuisance Statute's Safe-harbor; Preemption; R; PRE; CON; CU; AU; H; R; PRE; LF; T-MIL 7; J-MIL 4; J-MIL 8; J-MIL 12; T-MIL 6	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0287	"I Got My Life Back Part II, A Two-Year Follow-Up" Transcript	PKY180502085- PKY180502122		Cambra 4	Judicial Estoppel; Nuisance Statute's Safe-harbor; Preemption; R; PRE; CON; CU; AU; H; R; PRE; LF; T-MIL 7; J-MIL 4; J-MIL 8; J-MIL 12; T-MIL 6	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0288	Document entitled "For the video tape entitled 'From One Pain Patient to Another'"	PKY181678359 - PKY181678361		Cambra 5	Judicial Estoppel; R; PRE; CON; CU; AU; H; R; PRE; LF; T-MIL 7; J-MIL 4; J-MIL 8; J-MIL 12; T-MIL 6	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0289	Document entitled "From One Pain Patient to Another"	PKY183063607	PKY183063610	Cambra 6	Judicial Estoppel; R; PRE; CON; CU; AU; H; R; PRE; LF; T-MIL 7; J-MIL 4; J-MIL 8; J-MIL 12 T-MIL 6	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0290	Orbis Medical News Special Report, Chronic Pain: The Silent Epidemic, Final Draft	PKY181313468	PKY181313473	Cambra 7	Judicial Estoppel; R; PRE; CON; CU; AU; H; R; PRE; LF; T-MIL 7; J-MIL 4; J-MIL 8; INC; J-MIL 12	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0291	"Senate panel investigates drug companies' tie to pain groups," Article from the Washington Post			Cambra 8	H; R; AU; LF; PRE; T-MIL 7; J-MIL 4; J-MIL 8; INC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802

S-0292	"Marketing Tips"	PKY180133288	PKY180133289	Cambra 9	Judicial Estoppel; R; PRE; CON; CU; AU; H; R; PRE; LE; T-MIL 7; J-MIL 4; J-MIL 8; INC; J-MIL 12	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0293	Sales Bulletin	PKY180133971	PKY180133972	Cambra 10	Judicial Estoppel; R; PRE; CON; CU; AU; H; R; PRE; LE; T-MIL 7; J-MIL 4; J-MIL 8; INC; J-MIL 12	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0294	Partners against Pain Media Campaign Update	PKY180133570	PKY180133577	Cambra 11	Discovery Violations; Judicial Estoppel; R; PRE; CON; CU; AU; H; R; PRE; LE; T-MIL 7; J-MIL 4; J-MIL 8; INC; J-MIL 12	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0295	Memorandum to Purdue Board, Executive Vice Presidents, and Vice Presidents from Mark Alfonso	PKY180140726	PKY180140728	Cambra 12	Judicial Estoppel; R; PRE; CON; CU; AU; H; R; PRE; LE; T-MIL 7; J-MIL 4; J-MIL 8; INC; J-MIL 12	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0296	United States GAO Report to Congressional Requesters, "Prescription Drugs, OxyContin Abuse and Diversion and Efforts to Address the Problem"			Cambra 13	H; AU; LE; R; PRE; T-MIL 7; J-MIL 4; J-MIL 8; PR/AU; INC	12 O.S. 2802
S-0297	Email chain, Ending on the first page, From John Fauber to James Heins, et al.	PPLP004163476	PPLP004163480	Cambra 14	Judicial Estoppel; R; PRE; CON; CU; AU; H; R; PRE; LE; T-MIL 7; J-MIL 4; J-MIL 8	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0298	Handwritten Notes of Colligen			Colligen 1	AU; H; R; LE; PRE; CON; IC; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0299	The Pain Care Forum	JAN-MS-00934869		Colligen 2	First Amendment; AU; H	12 O.S. 2602, 12 O.S. 2901;
S-0300	E-mail	JAN-MS-0092262-664		Colligen 3	First Amendment; AU; H	12 O.S. 2602, 12 O.S. 2901;
S-0301	Pain Care Forum Agenda for 11/18	NPRO0001TPP00002718		Colligen 4	First Amendment; AU; H	12 O.S. 2602, 12 O.S. 2901;
S-0302	Pain Care Forum, 2010 Meetings Schedule	WISPPSG000008698		Colligen 5	AU; H; R; LE; PRE; J-MIL 3	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0303	Groups, Currently Partnering with Janssen	JAN-MS-00855080-084		Colligen 6	AU; H	12 O.S. 2602, 12 O.S. 2901;
S-0304	2013 National Advocacy Business Planning, Pain Franchise	JAN-MS-00405372		Colligen 7	First Amendment; AU; H	12 O.S. 2602, 12 O.S. 2901;
S-0305	Lunch Briefing Invitation, 15	PRO0001TPP00001837		Colligen 8	First Amendment; AU; H; LE; R; PRE; S; J-MIL 3	12 O.S. 2602, 12 O.S. 2901;
S-0306	Responsible Opioid Prescribing, A Physician's Guide			Colligen 9	AU; H; PRE; CON; CU; LE; R; PRE; INC; V	12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0307	PAINS Project	JAN-MS-00397451-464		Colligen 10	First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0308	Johnson & Johnson Request for Proposal			Colligen 11	AU; H; LF; R; PRE; PR/AU; IC; S; CON; INC; SUM	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0309	Email dated 3-35-3022 from R. Stough to C. Abraham and others (Confidential)	JAN-OK09133156		Hightower 1	AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0310	Email dated 1-20-2012 from E. Anderson to B. Hightower (Confidential)	JAN-OK-00134639		Hightower 2	AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0311	"Altitude: Reach New Heights" Powerpoint	JAN-MS-00089006	JAN-MS-00089037	Hightower 3	PRE; CU	
S-0312	Call Notes (portion) - Elizabeth Hightower & Elizabeth Wakefield	JAN-OK-00000001	JAN-OK00000004	Hightower 4	AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0313	Email dated 8-7-2010 from B. Hightower to C. Abraham (Confidential)	JAN-OK-00132937	JAN-OK-00132938	Hightower 5	AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0314	Email dated 9-18-2010 from B. Hightower to C. Abraham	JAN-OK-099133020	JAN-OK-00133021	Hightower 6	AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0315	Email dated 10-1-2010 from B ;Hightower to C. Abraham	JAN-OK-00133040		Hightower 7	AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0316	Representative Info Spreadsheet	JAN-MS-00748867		Hightower 8	R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0317	IM Retail PNMV \$25 Card and 10 Free Pill Voucher Allocation Program (Confidential)	JAN-MS-00865032		Hightower 9	R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0318	Tolled Plaintiffs (Confidential)	PKY183078268	PKY183078268	Hightower 10	Judicial Estoppel; R; PRE; CON; CU; AU; H; R; PRE; LF; T-MIL 7; J-MIL 4; INC; V; J-MIL 8	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0319	June 2012 emails	JAN-MS-00270295		Grubb 1	Nuisance Statute's Safe-harbor; R	12 O.S. 2401, 2402
S-0320	4/16/13 Emails	JAN-MS-00267003	JAN-MS-00267004	Grubb 2	Nuisance Statute's Safe-harbor; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0321	4/3/2015 email	JAN-MS-00264875		Grubb 3	AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0322	1/25/16 emai with attachment, 2016 January Narcotics SOP.docx	JAN-MS-02964781	JAN-MS-02964816	Grubb 4	AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0323	June 2014 emails	JAN-MS-00429251	JAN-MS-00429252	Grubb 5	AU	12 O.S. 2602, 12 O.S. 2901

S-0324	August 2011 emails	JAN-MS-00935978	JAN-MS-00935979	Grubb 6	First Amendment; Nuisance Statute's Safe-harbor; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-0325	8/30/13 emails	JAN-MS-00265176		Grubb 7	H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602
S-0326	February 2014 emails with attachment	JAN-MS-02965202	JAN-MS-02965205	Grubb 8	AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-0327	September 2014 emails	JAN-MS-02965083	JAN-MS-02965085	Grubb 9	First Amendment; AU; H	12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-0328	The Tasmanian Poppy Industry: A Case Study of the Application of Science and Technology			Ex 7 Previously Marked	AU; H; R; PRE; CON; CU; IC; LF; J-MIL 4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-0329	Management Presentation - Noramco World Wide Narcotics Franchise	JAN-OK-00149992		Verheyen 24	PRE; CON; J-MIL #4; CU	
S-0330	October 19 of 1999 E-mail	JAN-MS-01006281	JAN-MS-01006282	Verheyen 25	AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-0331	E-mail, December of 1999	JAN-MS-00267904		Verheyen 26	AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-0332	E-mail dated 12/7/1999	JAN-MS-00267905		Verheyen 27	AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-0333	February 18, 2000 e-mail chain	JAN-MS-00246903		Verheyen 28	AU; H	12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-0334	Barry Fitzsimons Deposition Transcript			Verheyen 29	Inadmissible Character Evidence; Nuisance Statute's Safe-harbor; R; PRE; CON; CU; H; R; AU; IC; LF; J-MIL 4; PRE	
S-0335	Noramco Sales Summary, December 2006	NORAMCO00000007		Verheyen 30	Nuisance Statute's Safe-harbor; AU; H; LF; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2901; 12 O.S. 2802
S-0336	Noramco Sales Summary, December 2007	NORAMCO00000008		Verheyen 31	Nuisance Statute's Safe-harbor; AU; H; LF; R; PRE	12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-0337	Noramco Sales Summary, December of 2008	NORAMCO00000009		Verheyen 32	Nuisance Statute's Safe-harbor; AU; H; LF; R; PRE	12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-0338	Excerpts from Bruce Colligen Deposition			Verheyen 33	First Amendment; Nuisance Statute's Safe-harbor; H; R; AU; IC; LF; J-MIL 4; PRE; CU; CON; IMC	12 O.S. 2401, 2402; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802

S-0339	Johnson & Johnson request for proposal			Verheyen 34	R; PRE; CON; CU; AU; H; LF; PRE; IC; S; INC; SUM	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0340	5/30/03 Email with Noramco Organizational Alignment Presentation	JAN-MS-00725218		Verheyen 35	CON; SUM	
S-0341	E-mail Chain, April 2, 2015	JAN-MS-02735300		Verheyen 36	AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0342	E-mail from Barry Fitzsimons dated May 1, 2003 with Actia presentation	JAN-MS-02760714		Verheyen 37	AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0343	6/29/2007 Email from L. Leonard to H. Tattel, R. Moreno, R. Kuntz - JAN-MS-00442057	JAN-MS-00442057		Kuntz 1	AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0344	PPT Slides Nonbranded promotion - JAN-MS-00442058	JAN-MS-00442058		Kuntz 2	PRE; AU; H; CON	
S-0345	PPT Slides APs Activities - JAN-MS-00271169	JAN-MS-00271169		Kuntz 3	First Amendment; AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0346	Nucynta Product Label			Kuntz 4	AU; H; LF; IC; T-MIL 8	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0347	Current Nucynta ER Package Insert			Kuntz 5	AU; H; LF; IC; T-MIL 8	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0348	Johnson & Johnson Request For Proposal			Kuntz 6	R; PRE; CON; CU; AU; H; LF; PRE; IC; S; INC; SUM	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0349	4/11/2014 Email from R. Kuntz to M. Proser, P. Quach, H. Rofael - JAN-MS-00422752	JAN-MS-00422752		Kuntz 7	AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0350	Nucynta Product Label or Insert	JAN-MS-00422753		Kuntz 8	PRE; CON; CU; AU; H; R	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0351	Defendants Janssen Pharmaceuticals, Inc.'s and Johnson & Johnson's Amended Answer to Plaintiff's Petition			Kuntz 9	AU; LF; H; PR/AU	
S-0352	6/29/12 PPT slides 2013 National Advocacy Business Planning - Pain Franchise June 29, 2012	JAN-MS-00405372		Kuntz 10	First Amendment; AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0353	12/10/2014 Email from B. Colligen to R. Kuntz, T. Davidson, H. Rofael	JAN-MS-000430125		Kuntz 11	First Amendment; AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0354	5/16/2014 Email from R. Kuntz to O. Jones, B. Murdock, P. Smylk	JAN-MS00266106		Kuntz 12	AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0355	3/10/2015 Email from R. Kuntz to F. Tewell	JAN-MS-00430843		Kuntz 13	First Amendment; R; PRE; CON; CU; AU; H; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0356	2/25/2014 Email from N. Arens to P. Carson and others	JAN-MS-00984596		Kuntz 14	First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0357	Tepeatadol Team Status- 4/15/2009- Acute Pain Publications - JAN-MS-00323320	JAN-MS-00323320		Kuntz 15	AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0358	1/21/2015 Email from R. Kuntz to B. Colligen - JAN-MS-00267288	JAN-MS-00267288		Kuntz 16	First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0359	4/1/20215 Email from R. Kuntz to G. Bilyk - JAN-MS-00417390	JAN-MS-00417390		Kuntz 17	AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0360	9/14/2011 - Article - Mechanisms of pain transmission and pharmacologic management			Kuntz 18	AU; H; LE; IC; CU; R; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0361	Eric Wayman's Resume	WAVMAN000001		Wayman 1	H; R; AU; LE; PRE; IC	12 O.S. 2401, 2402; 12 O.S. 2802
S-0362	Standard Operating Procedures	PKY180268536	PKY180268564	Wayman 2	AU; H; R; PRE; CON; CU; LE; T-MIL 4; J-MIL 7; J-MIL 12	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0363	Revised Standard Operating Policies	POK003279032		Wayman 3	AU; H; R; PRE; CON; CU; LE; T-MIL 4; J-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0364	"Targeting the High Prescribers"	PDD8901061478		Wayman 4	AU; H; R; PRE; CON; CU; LE; T-MIL 4; J-MIL 7; INC; J-MIL 16	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0365	"TRX Level is Highly Correlated to Call Activity"	PKY183117989		Wayman 5	AU; H; R; PRE; CON; CU; LE; T-MIL 4; J-MIL 7; J-MIL 12	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0366	"Source of Business"	PPLP003421615		Wayman 6	AU; H; R; PRE; CON; CU; LE; T-MIL 4; J-MIL 7; INC; V	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0367	"The Return of Topper's Club"	POK003278145		Wayman 7	AU; H; R; PRE; CON; CU; LE; T-MIL 4; J-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0368	7-10-09 Memo to Entire Sales Force from Windell Fisher	POK003278094		Wayman 8	AU; H; R; PRE; CON; CU; LE; T-MIL 4; J-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0369	The President's Commission on Combating Drug Addiction and the Opioid Crisis			Wayman 9	H; R; AU; LF; T-MIL 1	12 O.S. 2401, 2402; 12 O.S. 2802
S-0370	Wall Street Journal Article - " We make prescription opioids. And we want to limit their use."			Wayman 10	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7	12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-0371	Purdue Pharma website: "Ongoing Efforts"			Wayman 11	H; R; AU; LF; PRE; T-MIL 4; J-MIL 7; IC; CU; INC	12 O.S. 2401, 2402; 12 O.S. 2802
S-0372	Purdue Pharma website: "Open Letter"			Wayman 12	H; R; AU; LF; PRE; T-MIL 4; J-MIL 7; IC; CU; INC	12 O.S. 2401, 2402; 12 O.S. 2802
S-0373	Purdue Pharma website: "Prevention Education"			Wayman 13	H; R; AU; LF; PRE; T-MIL 4; J-MIL 7; IC; CU; INC	12 O.S. 2401, 2402; 12 O.S. 2802
S-0374	Purdue Pharma website: "What We're Doing Now"			Wayman 14	H; R; AU; LF; PRE; T-MIL 4; J-MIL 7; IC; CU; INC	12 O.S. 2401, 2402; 12 O.S. 2802
S-0375	Deactivated website: "In the Face of Pain"			Wayman 15	AU; H; R; LF; PRE; T-MIL 4; J-MIL 7; IC; CU; INC	12 O.S. 2401, 2402; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-0376	"Partners Against Pain"			Wayman 16	R; PRE; CON; CU; AU; H; PRE; LF; T-MIL 4; J-MIL 7; IC; J-MIL 12	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-0377	"Counseling Your Patients and Their Families Regarding the Use of Opioids to Relieve Pain"			Wayman 17	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; IC; J-MIL 12	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-0378	8-13-12 Email from James Heins to John Fauber Re: News Story About Oxycontin Video			Wayman 18	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-0379	3-9-07 Memo to Entire Sales Department from Roland Gustavson			Wayman 19	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-0380	Unavailable website url: www.partnersagainstpain.com			Wayman 20	R; AU; LF; H; PRE; T-MIL 4; J-MIL 7; INC; IC	12 O.S. 2401, 2402
S-0381	"Dr. Richard Sackler Addresses Purdue's Sales Force"			Wayman 21	H; R; AU; LF; PRE; T-MIL 4; J-MIL 7; IC; CON	12 O.S. 2401, 2402; 12 O.S. 2802
S-0382	6-2-97 Email from Michael Cullen re OxyContin Team Meeting Minutes			Wayman 22	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-0383	5-28-97 Email from Michael Friedman to Dr. Robert Kalko, et al.			Wayman 23	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802

S-0384	"Dispelling the Myths About Opioids" Fourth Quarter 2015 Incentive Program Territory Business Managers	PKY180120983			Wayman 24	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; IC; J-MIL 12	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0385		PPLP004426031	PPLP004426035		Wayman 25	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0386	9-14-15 Memo to Purdue Sales Force from Sales Operations	POK003279098			Wayman 26	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0387	1-9-15 Memo to Entire Sales Force from Jennifer Lynch	POK003276517			Wayman 27	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0388	4-8-15 Memo to Purdue Sales Force from Andrea Buechel	POK003276557			Wayman 28	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0389	1-9-14 Memo to Purdue Sales Force from Russ Gasdia	POK003276340			Wayman 29	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0390	5-5-15 Memo to Purdue Sales Force from Field Force Analytics	POK003276640			Wayman 30	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0391	11-4-96 Memo to Entire Field Force from Training & Development	PKY180239887	PKY180239889		Wayman 31	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; IC J-MIL 12	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0392	Amended Notice for 3230(c)(5) Videotaped Deposition of Corporate Representative(s) of Teva/Cephalon Defendants				Hassler 1	H; R; PRE; CU	12 O.S. 2802
S-0393	Fentora 2007 Marketing Plan PowerPoint	TEVA_OK_00039272			Hassler 2	R; PRE; CON; CU; AU; H; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0394	USA v. Cephalon, Inc. - Government's Memorandum for Entry of Plea and Sentencing	TEVA_OK_13597800			Hassler 3	PRE; CON; CU; H; R; AU; LF; T-MIL 5; PR/AU; SCOPE	12 O.S. 2401, 2402; 12 O.S. 2802
S-0395	5/3/05 Email from Chris Meyer to Todd Jones and Others - Subject: FW: region 65 Segmentation Reports	TEVA_OK_00944096			Hassler 4	R; PRE; CON; CU; AU; H; PRE; LF; V	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0396	5/17/05 Email from Chris Meyer to the West Region Management Team - Subject: Actiq Segementation Reports	TEVA_OK_0075607		Hassler 5	AU; H; R; LF; PRE; V; CON; J-MIL 16	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0397	Mission: Actiq 2005 PowerPoint	TEVA_OK_0078704		Hassler 6	AU; H; R; LF H CU R; PRE; IC; Scope	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0398	Cephalon Agenda Topics PowerPoint Draft - bFOCUSED in 2008 - Area Marketing and Field Effectiveness - bFOCUSED "In Action"	TEVA_OK_00744220		Hassler 7	R; PRE; CON; CU; AU; H; PRE; LF; SCOPE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0399	5/23/07 Thomas Mosley Teva Field Contact Report	TEVA_OK_00535492		Hassler 8	R; PRE; CON; CU; AU; H; PRE; LF; Scope; INC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0400	Fentora ACM - Q/A Grid Based on March 19/20 Working Session and Mock Meeting A March 31 (Day 1)	TEVA_OK_03148378		Hassler 9	AU; H; R; LF; PRE; CU; Scope; CON; INC	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0401	Fentora Prescriber Targeting Report - Excel Spreadsheet	TEVA_OK_0122243		Hassler 10	AU; H; R; LF; PRE; V; CON; INC; IC; J-MIL 16	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0402	Cephalon Sales Operations Practitioner Promotional Classification - Do Not Promote/ do Not Call Documentation	TEVA_OK_00891848		Hassler 11	AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0403	July 2013 Email Chain from Bradley Sloan to Nancy Reigel and Others - Subject: Re: AccessMonitor and Teva CNS	TEVA_OK_00937431		Hassler 12	AU; H; R; LF; CON	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0404	Deposition Subpoena			Featherstone 1	H; R; PRE; CU	12 O.S. 2802
S-0405	I Got My Life Back	PKY183067429	PKY183067438	Featherstone 2	First Amendment; Judicial Estoppel; R; PRE; CON; CU; AU; H; R; PRE; LF; T-MIL 4; J-MIL 7; IC; J-MIL 12	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0406	Dispelling the Myths about Opioids	PKY180120983		Featherstone 3	First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; IC; J-MIL 12	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0407	Production from Featherstone	Featherstone0000001	Featherstone0000081	Featherstone 4	AU; H; R; LF; PRE; T-MIL 4; J-MIL 7; IC; J-MIL 12; CON; CU; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0408		Featherstone0000082	Featherstone0000094	Featherstone 5	AU; H; R; LF; PRE; T-MIL 4; J-MIL 7; IC; J-MIL 12; CON; CU; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0409	Christopher Moses Summary	POK003287419-420		Featherstone 6	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; J-MIL 16; V; S	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0410	Tulsa World - "Eight Overdose Deaths Spur DEA Investigation of South Tulsa Doctor"			Featherstone 7	Judicial Estoppel; R; PRE; CON; CU; AU; H; R; PRE; LF; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0411	NewsOK - "Two Doctors Accused in Indictment of Operating Pill Mill in Shawnee"			Featherstone 8	AU; H; LF; R; PRE; IC	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0412	Call Reports	POK003287903-919		Featherstone 9	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; J-MIL 16; V; S	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0413	Dennis Roberts Summary	POK003287925-926		Featherstone 10	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; J-MIL 16; V; S	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0414	Dr. Kalvin White	POK003288395-430		Featherstone 11	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; J-MIL 16; V; S	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0415	Dr. Glenn Stow	POK003288125-141		Featherstone 12	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; J-MIL 16; V; S	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0416	Call Notes	POK001852070		Featherstone 13	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; J-MIL 16; V; S	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0417	American Pain Society Mission page			Reisner 1	First Amendment; H; R; AU; LF; PRE; IC; J-MIL 3	12 O.S. 2401, 2402; 12 O.S. 2802
S-0418	American Pain Society News - President's Response to McCaskill Report			Reisner 2	First Amendment; AU; H; R; LF; PRE; IC; J-MIL 3; Scope	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0419	American Pain Society Payments	APS-SUPP00000614		Reisner 3	First Amendment; H; AU; LF; R; PRE; IC; J-MIL 3	12 O.S. 2802
S-0420	The 26th Annual Scientific Meeting of the American Pain Society - May 3-5, 2007			Reisner 4	First Amendment; AU; H; R; LF; PRE; IC; J-MIL 3	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0421	American Pain Society Written Agreement for Commercial Support	APS-MDL00000406		Reisner 5	First Amendment; AU; H; R; LF; PRE; IC; J-MIL 3	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0422	American Pain Society E-News				Reisner 6	First Amendment; H; R; AU; LF; PRE; IC; J-MIL 3	12 O.S. 2401, 2402; 12 O.S. 2802
S-0423	American Pain Society E-News				Reisner 7	First Amendment; AU; H; R; LF; PRE; IC; J-MIL 3	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0424	The Use of Opioids for the Treatment of Chronic Pain	APS-MDL00000058			Reisner 8	AU; LF; H; R; PRE; IC; J-MIL 3	
S-0425	American Society of Addiction Medicine - Definitions Related to the Use of Opioids for the Treatment of Pain: Consensus Statement of the American Academy of Pain Medicine, the American Pain Society, and the American Society of Addiction Medicine				Reisner 9	First Amendment; Nuisance Statute's Safe-harbor; Preemption; AU; H; R; LF; PRE; IC; J-MIL 3	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0426	The Pain Care Forum Need	JAN-MS-00934869			Reisner 10	First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0427	Pain Care Forum 2009 Meetings Schedule	WISPPSG00008035	WISPPSG00008046		Reisner 11	First Amendment; AU; H; LF; R; PRE; IC; J-MIL 3; S; Scope	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0428	Reisner notes brought to deposition (list Cathy Underwood made of list of acronyms APS used frequently)				Reisner 12	First Amendment; AU; H; R; LF; PRE; IC; J-MIL 3; CON; V	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0429	Pain Care Forum 2010 Meetings Schedule	WISPPSG00010776			Reisner 13	AU; LF; H; R; PRE; IC; J-MIL 3; S; Scope	
S-0430	Pain Care Forum 2011 Meetings Schedule	WISPPSG00011543	WISPPSG00011555		Reisner 14	First Amendment; AU; H; LF; R; PRE; IC; J-MIL 3; S; Scope	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0431	Printout from American Pain Society website: "Pain Care Coalition"				Reisner 15	First Amendment; H; R; AU; LF; PRE; IC; J-MIL 3	12 O.S. 2401, 2402; 12 O.S. 2802
S-0432	Leadership Summit On Pain Management Invitation	PDD1502321158	PDD1502321161		Reisner 16	First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; IC; S; V	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0433	Article: "Chronic Pain In America: Roadblocks to Relief"				Reisner 17	Discovery Violations; First Amendment; R; PRE; CON; CU; AU; H; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0434		APS-SUPP00000603			Reisner 18	First Amendment; H; R; AU; LF; PRE; IC; J-MIL 3	12 O.S. 2401, 2402; 12 O.S. 2802

S-0435	Pain: The Fifth Vital Sign - Five Things You Can Do to Improve Pain Assessment and Treatment	APS-SUPP00000561		Reisner 19	First Amendment; AU; H; R; LF; PRE; IC; J-MIL 3	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0436	American Pain Society - "Corporate Council"			Reisner 20	First Amendment; H; R; AU; LF; PRE; IC; J-MIL 3	12 O.S. 2401, 2402; 12 O.S. 2802
S-0437	American Pain Society Website - Corporate Council - Connect Directly with Pain Professionals			Reisner 21	First Amendment; H; R; AU; LF; PRE; IC; J-MIL 3	12 O.S. 2401, 2402; 12 O.S. 2802
S-0438	American Pain Society Website - Corporate Council Members, Corporate Circle Level			Reisner 22	First Amendment; AU; H; R; LF; PRE; IC; J-MIL 3	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0439	The President's Commission on Combating Drug Addiction and the Opioid Crisis (portion)			Reisner 23	H; R; PRE; CON; CU; AU; LF; IC; J-MIL 3; Scope	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802
S-0440	The Wall Street Journal - "A Pain-Drug Champion Has Second Thoughts"			Reisner 24	Discovery Violations; Nuisance Statute's Safe-harbor; R; AU; LF; H; PRE; IC CU; Scope	12 O.S. 2401, 2402
S-0441	American Pain Society website printout- "Message from the President About the CDC Guidelines"			Reisner 25	First Amendment; H; R; AU; LF; PRE; IC; J-MIL 3	12 O.S. 2401, 2402; 12 O.S. 2802
S-0442	HSGAC Fueling an Epidemic			Reisner 26	First Amendment; H; PRE; CON; CU; AU; LF; R; IC; Scope	12 O.S. 2403; 12 O.S. 2802
S-0443	Affidavit of Cathering H. Underwood, MBA, CAE	APS-MDL000000054		Reisner 27	AU; LF; H	
S-0444	Affidavit of Gregory Terman, MD PHD	APS-MDL000000056		Reisner 28	AU; LF; H	
S-0445	Opioid Treatment Guidelines - Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain	APS-MDL00000140		Reisner 29	AU; LF; H; R; PRE; IC; J-MIL 3	
S-0446	Guideline for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain - Evidence Review	APS-MDL00000186		Reisner 30	AU; LF; H; R; PRE; IC; J-MIL 3	
S-0447	ACCME - Standards for Commercial Support	JAN-MS-00441115		Reisner 31	AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0448	"Painkiller panel drops experts linked to pharma industry"			Reisner 32	First Amendment; AU; H; R; LF; PRE; IC; J-MIL 3; Scope	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0463	Email from Gary Vorsanger re March 2008 Agenda	JAN-MS-02149086			Moskovitz 15	First Amendment; H	12 O.S. 2802
S-0464	Johnson & Johnson Outline of Radio Show Proposal	JAN-MS-00483593	JAN-MS-00483595		Moskovitz 16	AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0465	Substance Use Disorders in a Primary Care Sample Receiving Daily Opioid Therapy				Moskovitz 17	AU; LF; H; R; PRE; IC; Scope; CU; T-MIL 1	
S-0466	Opioid Use Behaviors Mental Health and Pain - Development of a Typology of Chronic Pain Patients				Moskovitz 18	Nuisance Statute's Safe-harbor; Preemption; AU; LF; H; R; PRE; IC; Scope; CU; T-MIL 1	
S-0467	Risk Factors for Drug Dependence Among Out-Patients on Opioid Therapy in a Large US Health-Care System				Moskovitz 19	First Amendment; Judicial Estoppel; R; PRE; CON; CU; AU; H; R; PRE; LF; IC; Scope; T-MIL 1	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0468	What Percentage of Chronic Nonmalignant Patient Patients Exposed to Chronic Opioid Analgesic Therapy Develop Abuse/Addiction and/or Aberrant Drug-Related Behaviors?				Moskovitz 20	AU; LF; H; R; PRE; IC; Scope; CU; T-MIL 1	
S-0469	Long-Term Opioid Management for Chronic Noncancer Pain				Moskovitz 21	AU; LF; H; R; PRE; IC; Scope; CU; T-MIL 1	
S-0470	Prospective Evaluation: Evaluation about the Abuse of Prescription and Illicit Drugs in Chronic Patients Receiving Short-Acting (Hydrocodone) or Long-Acting (Methadon) Opioids				Moskovitz 22	AU; LF; H; R; PRE; IC; Scope; CU; T-MIL 1	
S-0471	ScienceDirect Article - Hydrocodone - an overview				Moskovitz 23	AU; LF; H; R; PRE; IC; Scope; CU; T-MIL 1	
S-0472	JAN-MS-00493882 with attachment	JAN-MS-00493882			Moskovitz 23A	CU; PRE	
S-0473	CU Review of Iatrogenic Addiction Associated with the Use of Transdermal Duragesic (fentanyl) Patch	JAN-MS-02754767	JAN-MS-02754783		Moskovitz 24	H; INA; CU	
S-0474	Johnson & Johnson Request for Proposal	JAN-OK-00148072	JAN-OK- 00148075		Moskovitz 25	J-MIL #9; PO; INA; PRE	
S-0475	Highlights of Prescribing Information				Moskovitz 26	AU; LF; H; IC; Scope CU T-MIL 8	12 O.S. 2602, 12 O.S. 2901

S-0476	Pseudobaddiction: Fact or Fiction. An investigatoin of the medical literature			Hassler 1	First Amendment; R; PRE; CON; CU; AU; H; PRE; LF; R; IC	12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0477	The Continued Rise of Opioid Misuses, Opioid-use Disorder; Report by Bill McCarberg			Hassler 2	First Amendment; R; PRE; CON; CU; AU; H; PRE; LF; R; IC	12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0478	Email dated 8-24-2015 to J. Hassler	TEVA_OK_07210926		Hassler 3	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; IC; Scope	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0479	3230 ©(5) Deposition Notice			Hassler 4	H; R; PRE; CU	12 O.S. 2802
S-0480	MedPage Today article - "Chronic Pain Fuels Boom in Opioids"			Hassler 5	First Amendment; R; PRE; CON; CU; AU; H; PRE; LF; R; IC; Scope	12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0481	Excerpt from "Responsible Opioid Prescribing"			Hassler 6	First Amendment; R; PRE; CON; CU; AU; H; PRE; LF; R; IC; Scope; INC	12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0482	"The Epidemic of Pain in America" dated 6-13-2006 (portion)	PPLP004326800	PPLP004326932	Hassler 7	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; IC; Scope; PR/AU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0483	"Making Pain Talk Painless; A Guide to help you talk with your doctor about pain management"	TEVA_OK_00116233		Hassler 8	First Amendment; AU; H; LF; R; PRE; Scope; CON	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0484	PowerPoint titled "Directors meeting Actiq December 2nd, 2004"	TEVA_OK_00044404		Hassler 9	R; PRE; CON; CU; AU; H; PRE; LF; Scope	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0485	Actiq Learning System Document	TEVA_OK_00115228		Hassler 10	AU; H; R; LF; PRE; Scope	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0486	Fentora Brand Plan 2008 (section)	TEVA_OK_00039464		Hassler 11	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; Scope; INC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0487	Emerging Solutions in Pain 2253 Form, Transmittal of Advertisements and Promotional Labeling	TEVA_OK_00523041		Hassler 12	First Amendment; AU; H; LF; R; PRE; Scope	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0488	2253 Form, Transmittal of Advertisements and Promotional Labeling	TEVA_OK_00010978		Hassler 13	AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0489	Pain Medicine, Independent Medical Education, Year-End Report for 2006	TEVA_OK_00502486		Hassler 14	First Amendment; AU; H; R; LF; PRE; Scope; SUM	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0490	Executive Summary	TEVA_OK_00116734		Hassler 15	First Amendment; AU; H; LF; R; PRE; Scope; SUM	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0491	Cephalony/Teva Tool Kit	TEVA_OK_00514808		Hassler 16	First Amendment; AU; H; R; LF; PRE; Scope; INC; CON	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0492	Notice of Deposition			McGuire 1	R; PRE; CU	
S-0493	Binder put together by witness	PPLP004487780	PPLP004487916	McGuire 2	Nuisance Statute's Safe-harbor; AU; H; R; PRE; CON; CU; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0494	October 15, 1998 Letter	PKY180867054	PKY180867055	McGuire 3	Nuisance Statute's Safe-harbor; AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; J-MIL 12; J-MIL 4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0495	OxyContin Chart (1996-1999)	PPLP004487919	PPLP004487924	McGuire 4	Nuisance Statute's Safe-harbor; AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; J-MIL 4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0496	Hysingla Chart (2014-2018)	PPLP004487925	PPLP004487925	McGuire 5	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; J-MIL 4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0497	Butrans Chart (2010-2013)	PPLP004487926	PPLP004487927	McGuire 6	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; J-MIL 4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0498	Rhodes Technologies 1st Qtr. 2001 Report	PDD9316315093	PDD9316315111	McGuire 7	Nuisance Statute's Safe-harbor; R; PRE; CON; CU; AU; H; R; PRE; LF; T-MIL 4; J-MIL 7; J-MIL 4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0499	August 29, 2005 Letter from Mahoney	PDD9316314676	PDD9316314704	McGuire 8	Nuisance Statute's Safe-harbor; AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; J-MIL 4; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0500	Excerpts from 2006 Update	PDD8901791203		McGuire 9	Nuisance Statute's Safe-harbor; AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; J-MIL 4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0501	Excerpts from "Supply Chain" Document	PDD9316315491	PDD9316315491	McGuire 10	Nuisance Statute's Safe-harbor; AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; J-MIL 4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0502	"Shake-up on Opium Island" Article	PPLP004487982	PPLP004487993	McGuire 11	Nuisance Statute's Safe-harbor; AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; J-MIL 4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0503	Excerpts from Noramco World Wild Doc.	PPLP004487994	PPLP004487997	McGuire 12	Nuisance Statute's Safe-harbor; AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; J-MIL 4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0504	Amended Notice for 3230©(5) Videotaped Deposition of Corporate Representative of J&J Defendants				KDE 1		R; PRE; CU	
S-0505	Duragesic Disease Modeling Workshop 2 Takeaways	JAN-MS-00481547			KDE 2		J-MIL #17; CON; AU; H; PRE	
S-0506	Notes re Databases and Analytics that the witness brought				KDE 3		H	12 O.S. 2802
S-0507	PriCara Pain Nucynta Contest - Right Now - 2010 Incentive Compensation & Recognition Plan	JAN-MS-00862041			KDE 4		AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0508	Nucynta 2011 Business Plan 7-27-10	JAN-MS-00132333			KDE 5		PRE; CON; SUM	
S-0509	Duragesic Market Update	JAN-MS-00311782			KDE 6		AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0510	Duragesic Fentanyl Transdermal System Document	JAN-MS-00310227			KDE 7		AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0511	8-11-04 Duragesic Business Update	JAN-MS-00479441			KDE 8		AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0512	Nucynta & Nucynta ER 2012 Business Plan	JAN-MS-00010801			KDE 9		PRE; CON; SUM	
S-0513	Nucynta ER/Nucynta Pain Force Core Targets	JAN-MS-0058862			KDE 10		AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0514	Ken Murphy - Pain Force State Date: 05/06/13	JAN-MS-00982436			KDE 11		First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0515	Training Workshops - Nucynta/Nucynta ER	JAN-MS-00668921			KDE 12		CON; PRE; CU; SUM	
S-0516	9-20-11 Email from Nithya Desikan to Elizabeth Biancani	JAN-MS-00348714			KDE 13		AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0517	OxyContin Top 500 Prescribers	PDD1782034498		PDD1782034509	Cramer 1		Nuisance Statute's Safe-harbor; Preemption; AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; INC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0518	Thought Leaders	PDD1782027773		PDD1782027793	Cramer 2		AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; INC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0519	4/17/02 - 4/18/02 Email Chain	PKY183405326		PKY1834055328	Cramer 3		PRE; CON; CU; AU; H; R; LF; T-MIL 4; J-MIL 7; J-MIL 12; T-MIL 1; J-MIL 8	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0520	Purdue OxyContin Marketing Document	PDD17070114811	PDD170701144869	Cramer 4	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; J-MIL 12; 5	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0521	Phase IV OxyContin Tablets Team Meeting Minutes - June 13, 1997	PPLP004030366	PPLP004030369	Cramer 5	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0522	Physician's Pain Management Speakers Training Program Slides	PDD1503911004	PDD1503911097	Cramer 6	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0523	Partners Against Pain National Speakers Training Program October 1-3, 1999	PDD150390113	PDD1503901231	Cramer 7	First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; V	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0524	Purdue Sales & Marketing Budget Meetings	PDD8901061469	PDD8901061637	Cramer 8	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; T-MIL 4; J-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0525	5/22/2000 and 7/31/2000 Leadership Summit on Pain Management	PDD1502321109	PDD1502321148	Cramer 9	AU; LF; H; R; PRE; T-MIL 4; J-MIL 7; J-MIL 3; IC	
S-0526	3/27/12 Email from Karen Ventrella to Denis Keohane - Purdue Internal Publication of Job Posting for Director of Medical & Scientific Affairs	POK003359093	POK003359094	Cramer 10	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0527	Purdue Sales Department Overview, Lecture Program Department Information, Purdue Training Courses, Etc.	PDD1502329956	PDD1502330068	Cramer 11	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0528	6/11/01 Letter to Valued Speaker from Joseph DaBronzo	PDD1502335932	PDD1502335932	Cramer 12	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0529	Purdue Lecture Program Department - A Field Force Guide to Setting Up Lecture Programs - Version I, April 2001	PDD1701191152	PDD1701191202	Cramer 13	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0530	Purdue Speakers Bureau Speaker Recommendation Form	PDD1701311426	PDD1701311428	Cramer 14	AU; LF; H; R; PRE; T-MIL 4; J-MIL 7	
S-0531	8/14/97 Purdue Sales Bulletin From Jim Lang to Entire Field Force	PKY180241316		Cramer 15	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; J-MIL 12	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0532	Budget Estimates for Purdue Advocacy Network	PKY183071994	PKY183071994	PKY183071994	Cramer 16	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; J-MIL 12; V	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0533	5/4/2000 Purdue Pharma, LP, Medical Education System Program Summary Fact Sheet	PDD1701295221	PDD1701295224	PDD1701295224	Cramer 17	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; INC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0534	7/3/08 Email Chain Between James Heins and Mike Meo	PKY183402297	PKY183402299	PKY183402299	Cramer 18	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; J-MIL 12	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0535	Proposed Target KOLs for PPR Communications	PPLP004268991			Cramer 19	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; IC; S; V; INC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0536	Pain and Policy Support Group: Radio Media Tour Budget Estimate Updated by Cooney Waters Group: July 9, 2008	PKY183402295	PKY183402296	PKY183402296	Cramer 20	First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; J-MIL 12; J-MIL 3	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0537	1/20/99 Creative Services Copy Clearance	PDD1701118803	PDD1701118812	PDD1701118812	Cramer 21	R; PRE; CON; CU; AU; H; PRE; LF; T- MIL 4; J-MIL 7; INC; P	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0538	1/31/01 Letter from Maria Marcuccilli to Michael Schwartz, M.D.	PDD1701293501	PDD1701293501	PDD1701293501	Cramer 22	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0539	Email Chain Including a 12/27/2000 Email from Kathy Walsh to Beverly Sackler and Others - Subject: Press Coverage of JCAHO Pain Guidelines	PKY183308648	PKY183308651	PKY183308651	Cramer 23	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; T-MIL 4; J-MIL 7; J- MIL 12; J-MIL 3	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0540	Purdue Speaker Request and Expense Forms	PDD1701286216	PDD1701286226	PDD1701286226	Cramer 24	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0541	3/24/01 Letter from Alan Spanos to Chris Neumann - Re: Fee Schedule for Lecturing	PDD1701259872	PDD1701259873	PDD1701259873	Cramer 25	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0542	7/7/2000 Email from David Haddox to Neil Irluck - Subject: Request	PKY183053382	PKY183053383	PKY183053383	Cramer 26	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; J-MIL 12; J-MIL 3	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0543	The Truth About Pain Management - Partners Against Pain Article	PKY183027554			Cramer 27	First Amendment; Judicial Estoppel; R; PRE; CON; CU; AU; H; R; PRE; LF; T-MIL 4; J-MIL 7; J-MIL 12; J-MIL 3; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0544	12/22/97 Letter of Agreement Between Oklahoma Osteopathic Association and Purdue	PDD17001727396			Cramer 28	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; J-MIL 3	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0545	7/9/98 Purdue Speaker Confirmation & Follow-Up Form	PDD1701229096	PDD1701229096		Cramer 29	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0546	12/23/01 New York Times Article - "Doctor to Face U.S. Charges in Drug Case"				Cramer 30	H; AU; LF; R; PRE; T-MIL 1 T-MIL 4; J-MIL 7	12 O.S. 2802
S-0547	Medical Liaison Report - Howard Berkowitz	PDD1701081872			Cramer 31	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0548	10/23/14 Email from James Heins to Charles Argoff - Subject: Re: Greetings and Question	ARGOFF003331	ARGOFF003338		Cramer 32	AU; H; R; LF; PRE; CON; IC; J-MIL 3; T-MIL 4; J-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0549	Purdue Pharma, LP, and Associated U.S. Companies Standard Operating Procedure	PPLP003398711	PPLP003398732		Cramer 33	AU; H; R; PRE; CON; CU; LF; T-MIL 4; J-MIL 7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0550	Printout from Medscape.com - "Should Hydrocodone Be Rescheduled", Charles E. Argoff				Argoff 1	AU; H; R; LF; PRE; IC; CU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0551	Supplement in the JAOA Journal - "Pharmacological management of chronic pain", Charles E. Argoff				Argoff 2	H; R; INC; 2701; PRE; T-MIL-8	12 O.S. 2401, 2402; 12 O.S. 2802
S-0552	Excerpt, "Defeat Chronic Pain Now", Charles Argoff				Argoff 3	AU; H; R; INC; 2701; PRE; T-MIL-8	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0553	Print-off from a website (ProPublica - Dollars for Docs - Charles Argoff - 2013)				Argoff 4	AU; H; INC; INA, LF; SUM; PRE; R	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0554	Print-off from a website (ProPublica - Dollars for Docs - Charles Argoff - 2014))				Argoff 5	AU; H; INC; INA, LF; SUM; PRE; R	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0555	Butrans Fibromyalgia Advisory Board Meeting	PPLPC029000500807	PPLPC029000500813		Argoff 6	AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0556	Email	ARGOFF000683	ARGOFF000684		Argoff 7	AU; H; R; PRE; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0557	Purdue Advisory Board Meeting - Observer's Guide	PPLP003391142	PPLP003391158	Argoff 8	AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0558	Email	ARGOFF000320	ARGOFF000320	Argoff 9	AU; H; R; PRE; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0559	Purdue Portfolio Advisory Board	PPLP004333825		Argoff 10	AU; H; R; PRE; CON; CU; LF; T-MIL-4; INC	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0560	Email	ARGOFF000415	ARGOFF000416	Argoff 11	AU; H; R; PRE; V	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0561	Draft Meeting Minutes for 2011 Fentora Medical/Scientific Advisory Board	TEVA_OK_01992263		Argoff 12	AU; H; R; PRE; CON; CU; LF; IC	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0562	Tapentadol IR in Low-Back Pain Protocol	JAN-MS-00722804	JAN-MS-00722816	Argoff 13	AU; H; LF; IC; R; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0563	Janssen Advisory Board Meeting	JAN-MS-00664902	JAN-MS-00664922	Argoff 14	H; R; LF; IC; PRE	12 O.S. 2401, 2402; 12 O.S. 2802
S-0564	KOL Immersion Training	JAN-MS-000194303	JAN-MS-00019408	Argoff 15	AU; H; LF; IC; R; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0565	Nucynta ER Extended Team Meeting	JAN-MS-00015057		Argoff 16	AU; H; LF; IC; R; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0566	Counseling Your Patients and Their Families Regarding the Use of Opioids to Relieve Pain	PKY180112565		Argoff 17	R; PRE; CON; CU; AU; H; PRE; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0567	Email	ARGOFF00331		Argoff 18	AU; H; R; LF; PRE; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0568	Press release - Purdue Pharma LP Receives FDA Approval for Hysingla ER (hydrocodone bitartrate) Extended-Release Tablets CII, A Once-Daily Opioid Analgesic Formulated with Abuse-Deterrent Properties			Argoff 19	AU; H; R; PRE; LF; SUM; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0569	Tapentadol Team Status June 24, 2009 Acute Pain Publications	JAN-MS-00323309		Argoff 20	PRE; R; H; AU; LF	
S-0570	Fueling an Epidemic - Report Two			KDE 14	First Amendment; AU; H; LF; SUM; PR/AU; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0588	Letter from Windell or Russ, May 2007	PCA000010590	PCA00010630	Cramer 35	AU; H; PRE; R; LF; T-MIL-4; INC	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0589	Monthly List of Top 200 Prescribers dated 10-15-2002	PDD1503450011	PDD1503450024	Cramer 36	AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0590	Indicators of Possible Diversion	PPLP004487264	PPLP004487265	Cramer 37	AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0591	Excerpts from the Original OxyContin Launch Plan in 9-27-1995	PDD1502302206		Cramer 38	AU; H; R; PRE; CON; CU; LF; T-MIL-4; INC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0592	Sales and Marketing Budget Meeting PowerPoint	PDD1701049274	PDD1701049274	Cramer 39	AU; H; R; PRE; CON; CU; LF; T-MIL-4; V	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0593	Email dated 9-30-1996 from R. Gasdia to M. Innaurato	PDD8901061469	PDD8901061551	Cramer 40	AU; H; R; PRE; CON; CU; LF; T-MIL-4; INC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0594	OxyContin 2012 ACAM Part II	PKY183117966	PKY183118028	Cramer 41	AU; H; R; PRE; CON; CU; LF; T-MIL-4; INC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0595	Memo from Sales Operations dated 6-9-2014 to District Managers	POK003276766	POK003276777	Cramer 42	AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0596	Memo to Purdue Sales Force dated 5-5-2015	POK003276640	POK003276643	Cramer 43	AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0597	Purdue Early View Report Spreadsheet	PDD9320451222	PDD9320451643	Cramer 44	AU; H; R; PRE; CON; CU; LF; T-MIL-4; SUM	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0598	Excerpt from Call Notes of O. Bushaw	PPLP004487357	PPLP004487358	Cramer 45	AU; H; R; PRE; CON; CU; LF; T-MIL-4; J-MIL-16	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0599	Letter dated 1-7-2011 from W. Fisher to Sales Force Colleagues	PPLP0034330057	PPLP3430092	Cramer 46	AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0600	Updated SOP 1-2-2013	PPLP003430093	PPLP003430137	Cramer 47	AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0601	Email from R. Gasdia to Sales Division and Hospital Specialty Division dated 10-24-2001	PDD1706057640	PDD1706057641	Cramer 48	AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0602	Updated SOP 10-6-2003.	PDD1503493410	PDD1503493414	Cramer 49		AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0603	Updated SOP 1.7.1 6-15-2007 R. Abrams Presentation "The Abuse and Diversion Detection Program ('ADD Program') dated 3-24- 2010	PPLP004487447	PPLP004487450	Cramer 50		AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0604	SOP 9-2015 Emails related to "Do Not Call" List Doctors	PPLP004487451	PPLP004487485	Cramer 51		AU; H; R; PRE; CON; CU; Privileged; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0605	SOP 9-2015 Emails related to "Do Not Call" List Doctors	PPLP004487486	PPLP004487490	Cramer 52		AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0606	Email dated 2-25-2009 from L. Ouirrette to Purdue Employees	PNV000002609	POK003288299	Cramer 53		AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0607	Subpoena for Deposition to a Non-Party	POK003287489	POK003287490	Cramer 54		AU; H; R; PRE; CON; CU; Privileged; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0608	Letter 6-7-12 to Chairman Baucus and Senator Grassley WISPPSG 415511-19	WISPPSG415511	WISPPSG415519	Mount 1		R; PRE; CU	
S-0609	UW-Madison Pain & Policy Studies Group Funding Award Information Cancer Pain Relief Newsletter Funding	WISPPSG00415633	WISPPSG 415648	Mount 2		H; R; PRE; LF; AU	12 O.S. 2401, 2402; 12 O.S. 2802
S-0610	Spring 2012 Outside Activities Report, WISPPSG 415642-48	WISPPSG 415642	WISPPSG 415648	Mount 3		H; R; PRE; IC	12 O.S. 2401, 2402; 12 O.S. 2802
S-0611	2016 Outside Activities Report - 11/28/2016, WISPPSG 415676-78	WISPPSG 415676	WISPPSG 415678	Mount 4		First Amendment; AU; H; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0612	Spring 2003 Outside Activities & Financial Interests Disclosure Form	WISPPSG 00415849	WISPPSG 00415687	Mount 5		First Amendment; AU; H; R; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0613	Spring 2006 Outside Activities Report	WISPPSG 00415771	WISPPSG 00415662	Mount 6		AU; H; PRE; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0614	Spring 2009 Outside Activities Report	WISPPSG 00415771	WISPPSG 00415662	Mount 7		H; R; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2802
S-0615	Spring 2003 Outside Activities & Financial Interests Disclosure Form	WISPPSG 00415662	WISPPSG 00415662	Mount 8		First Amendment; H; R; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2802
S-0616	Spring 2003 Outside Activities & Financial Interests Disclosure Form	WISPPSG 00415662	WISPPSG 00415662	Mount 9		H; PRE; R; LF	12 O.S. 2802

S-0617	2014 Outside Activities Report WISPPSG 415715-19	WISPPSG 415715	WISPPSG 415719	Mount 10	First Amendment; H; R; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2802
S-0618	Spring 2011 Outside Activities Report, WISPPSG 415695-97	WISPPSG 415695	WISPPSG 415697	Mount 11	First Amendment; H; R; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2802
S-0619	Dr. Gilson's curriculum vitae			Gilson 1	H	
S-0620	Pain Care Forum, 2010 Meeting Schedule	JAN-MS-00922357	JAN-MS-00922368	Gilson 2	PRE; R; H; LF; AU	
S-0621	Protective Order signed by Dr. Gilson			Gilson 3		
S-0622	Excerpt from "Responsible Opioid Prescribing, A Physician's Guide"			Gilson 4	First Amendment; AU; H; R; PRE; INC	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0623	Letter 7-23-02 and Model Guidelines	PKY181678252		Gilson 5	AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0624	"Trends in Medical Use and Abuse of Opioid Analgesics"			Gilson 6	H; R; PRE; PR/AU; 2701	12 O.S. 2401, 2402; 12 O.S. 2802
S-0625	"A Reassessment of Trends in the Medical Use and Abuse of Opioid Analgesics and Implications for Diversion Control:1997-2002"			Gilson 7	H; R; PRE; PR/AU; 2701	12 O.S. 2401, 2402; 12 O.S. 2802
S-0626	Letter from Pamela Bennett 8-22-00	PKY17011157443	PKY180377908	Gilson 8	AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0627	PowerPoint slides: Prescription Drug Overdose Epidemic and the Role of PDMPs in Stopping it - National Center for Injury Prevention and Control Centers for Disease Control and Prevention			Gilson 9	R; PRE; CON; CU; AU; H; PRE; PR/AU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0628	Issues Monitoring Report March 2001 Analysis	PKY183055774	PKY183055785	Gilson 10	AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0629	Bulletin 472000, from Medical Services, Product Management, Sales Training JAN-MS-02757597-598	JAN-MS-02757597-JAN-MS-02757598		Gilson 11	AU; H; PRE; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0630	"Increase in Unintentional Medication Overdose Deaths, Oklahoma 1994-2006"			Gilson 12	AU; H; R; PRE; LF; SUM	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0631	Letter from David Joranson and Aaron Gilson 6-6-06	WISPPSG00001919	WISPPSG00001921	Gilson 13	First Amendment; H; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2802
S-0632	External Affairs Group 2006 Accomplishments, 2007 Objectives, PPLP 4302663-688	PPLP004302663	PPLP004302688	Gilson 14	AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0633	Email string between James Heins, Mike Meo, et al., 7-9-08 - PKY183402294	PKY183402294	PKY183402294	Gilson 15	First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0634	Email string between James Heins, Mike Meo, et al., 7-3-08 and 6-25-08 PKY183402300-302	PKY183402300- PKY183402302		Gilson 16	First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0635	Pain Policy Overview 3-11-08	JAN-MS-00442778		Gilson 17	First Amendment; AU; H; R; PRE; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0636	Purdue Grants and Giving list PPLP3465329-349	PPLP3465329- PPLP3465349		Gilson 18	First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0637	Pain Care Forum meeting agenda 5-9-13, WISPPSG 18557	WISPPSG18557		Gilson 19	First Amendment; AU; H; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0638	"Achieving Balance in State Pain Policy, A Progress Report Card (CY 2013), TEVA-OK-03489648-693	TEVA-OK-03489648 - TEVA-OK-03489693		Gilson 20	First Amendment; AU; H; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0639	Proposal for Fentora Medical Scientific Advisory Board Teva-OK-00504579-581	OK-00504579	OK-00500504	Gilson 21	AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0640	Spring 2009 Outside Activities Report for Aaron Gilson	WISPPSG 00415771		Gilson 22	First Amendment; H; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2802
S-0641	Medical Affairs Analgesia Medical Science Liaison Report February 2004 -JAN-MS-00494929-940	JAN-MS-00494929	JAN-MS-00494940	Gilson 23	R; PRE; CON; CU; AU; H; PRE; LF	12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0642	Corporate Affairs and Communication Activities, Support for FDA Approval and Launch of Hysingla ER - PPLP004268968-9004	PPLP004268968	PPLP004269004	Gilson 24	AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0643	JCAHO Promotional Initiative PDD1782032086-2101	PDD1782032086	PDD1782032101	Gilson 25	AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0644	The President's Commission Report on Combating Drug Addiction and the Opioid Crisis			Gilson 26	H; R; PRE; CON; CU; AU; LF; PR/AU; T-MIL-1, SUIM	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802

S-0645	Purdue Table of Contents PKY180444978-5012	PKY180444978	PKY180445012	Gilson 27	First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0646	"Leadership Summit on Pain Management" agenda - PKY 180130001-40	PKY 180130001	PKY 180130040	Gilson 28	AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0647	Printout: "Advocacy Voices". In the Face of Pain			Gilson 29	AU; H; R; PR/AU; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0648	Pain Forum agenda 11-19-02 - JAN- MS-00614872-73	JAN-MS-00614872	JAN-MS-00614873	Gilson 30	First Amendment; AU; H; R; LF; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0649	Email string between David Joranson Aaron Gilson, et al., 1-5-05	WISPPSG00138977	WISPPSG00138978	Gilson 31	H; R; AU; PRE	12 O.S. 2401, 2402; 12 O.S. 2802
S-0650	Emails re: Questions to help us plan for 2010 budget	WISPPSG00138162	WISPPSG00138163	Gilson 32	First Amendment; H; R; AU; PRE	12 O.S. 2401, 2402; 12 O.S. 2802
S-0651	Letter from Frank Torti, Acting Commissioner of the Food and Drug Administration	WISPPSG00006691	WISPPSG00006693	Gilson 33	First Amendment; AU; H; R; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0652	Minutes from conference call of the American Pain Foundation BOD 6-26- 09	WISPPSG00007841	WISPPSG00007843	Gilson 34	First Amendment; AU; H; PRE; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0653	(no exhibit marked)			Gilson 35	AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403
S-0654	Attorney Brad Beckworth's contact information			Gilson 36	R; PRE; CON; CU	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0655	Responses to Topic 35, 36, 37			Fanelli 1	AU; H; SUM; PRE; R; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2802
S-0656	Corporate Relations Council			Saigh 1	First Amendment; H; R; PR/AU; PRE	12 O.S. 2401, 2402; 12 O.S. 2802
S-0657	Latest news from the American Academy of Pain Medicine			Saigh 2	First Amendment; H; R; PR/AU; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0658	2012-06-08 Letter re_ Relationship Between opioid Manufacturers and Health Care Organization	AAPM000000005	AAPM000000067	Saigh 3	First Amendment; AU; H; R; LF; PRE	12 O.S. 2401, 2402; 12 O.S. 2802
S-0659	2017-10-16 letter to Honorable McCaskill from Phillip Saigh	AAPM000000004	AAPM000000004	Saigh 4	First Amendment; H; R; PRE; INC	12 O.S. 2401, 2402; 12 O.S. 2802
S-0660	American Pain Medicine Spreadsheet	AAPM000000001	AAPM000000003	Saigh 5	First Amendment; H; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2802

S-0661	Spreadsheet								First Amendment; H; R; LF; PRE; SUM; AU	12 O.S. 2401, 2402; 12 O.S. 2802
S-0662	Amended Protective Order									
S-0663	Sponsorship Agreement				JAN-MS-00311782				First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0664	Pain Care Forum, Meeting Schedule				JAN-MS-00778989				LF; PRE; R; H; AU	
S-0665	External Affairs Group - 2006 Accomplishments 2007 Objectives								First Amendment; AU; H; R; PRE; LF; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0666	President's Declaration of Public Health Emergency								First Amendment; AU; H; R; PRE; LF; T-MIL-1, SUM	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0667	The President's Commission on Combating Drug Addictio and the Opioid Crisis								H; R; PRE; CON; CU; AU; LF; T-MIL-1, SUM	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802
S-0668	The Use of Opioids for the Treatment of Chronic Pain				JAN-MS-00500135				First Amendment; AU; H; LF; PRE; R; T-MIL-1	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0669	AAPM Releases Statement on the Diversion and Abuse of Controlled Substances				TEVA_OK_13727811				First Amendment; AU; H; R; PRE; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0670	Creative Services Copy Clearance				TEVA_OK_13727304				First Amendment; AU; H; R; PRE; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0671	Pain Advocacy Community								First Amendment; AU; H; R; PRE; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0672	Symposium Spotlight - Issue 4								First Amendment; AU; H; R; PRE; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0673	Letter to Acting Commissioner Torti				JAN-MS-01002292				First Amendment; AU; H; R; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0674	Email- from David Haddox to various RE_ Press Coverage Report from AAMed on FDA Rems								First Amendment; AU; H; R; PRE; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0675	Email from Psaigh to various RE_ FDA REMS Meetings				WISPPSG00415633				First Amendment; AU; H; R; PRE; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0676	AAPM Council of Past Presidents					Saigh 21	First Amendment; AU; H; R; PR/AU; PRE; IC	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0677	PPT- Update & National Advocacy Business Planning - Pain Franchise August 2012					Saigh 22	First Amendment; PRE; CON; CU; AU; H; PRE; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0678	Imagine the Possibilities- Building the Pain Coalition					Saigh 23	AU; H; PRE; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0679	Response to Inquiries about Payments from Opioid Manufacturers	FSMB00000017				Saigh 24	First Amendment; H; R; PRE; AU; IC	12 O.S. 2401, 2402; 12 O.S. 2802
S-0680	Standards for Commercial Support- Standards to Ensure the Independence fo CME Activities					Saigh 25	H; R; PRE; AU; PR/AU; LF	12 O.S. 2401, 2402; 12 O.S. 2802
S-0681	AAPM Statement on National Decline in Opioid Prescribing	PPLPC030000204729				Saigh 26	First Amendment; AU; H; R; PRE; CON; CU; PR/AU; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0682	Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain	JAN-OK-00149914				Saigh 27	PRE; R; H; AU; PR/AU; LF	
S-0683	Use of Opioids for the Treatment of Chronic Pain					Saigh 28	First Amendment; H; R; PRE; AU; PR/AU; LF	12 O.S. 2401, 2402; 12 O.S. 2802
S-0684	Corporate Members - Abbott Laboratories	JAN-MS-00618658				Saigh 29	First Amendment; AU; H; R; PRE; PR/AU; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0685	Corporate Members- Member profiles	JAN-MS-01002292				Saigh 30	First Amendment; AU; H; R; PRE; PR/AU, LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0686	Corporate Members- Corporate Member Profiles					Saigh 31	First Amendment; AU; H; PRE; R; PR/AU; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0687	Corporate Members- Corporate Member profiles					Saigh 32	First Amendment; AU; H; PRE; R; PR/AU; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0688	Corporate Members- Corporate Member Profiles					Saigh 33	First Amendment; AU; H; PRE; R; PR/AU; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0689	Department of Justice Press Release					Tewell 1	Inadmissible Character Evidence; R; PRE; CON; CU; AU; H; R; PRE; PR/AU; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0690	5/22/2014 Email from F. Tewell to M. Goodridge - JAN-MS-01968026	JAN-MS-01968026				Tewell 2	R; PRE; CON; CU; AU; H; PRE; PR/AU; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0691	5/1/2014 Email from O. Bock to F. Tewell, T. Davidson - JAN-MS-00577431	JAN-MS-00577431	Tewell 3	AU; H; R; PRE; PR/AU; LF; INC	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0692	Article - OxyContin- Purdue Pharma's painful- medicine - JAN-MS-00577432	JAN-MS-00577432	Tewell 4	AU; H; R; PRE; PR/AU; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0693	11/6/2014 Email from F. Tewell to O. Bock - JAN-MS-01969185	JAN-MS-01969185	Tewell 5	AU; H; PRE; R	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0694	9/29/2014 Email from F. Twell to D. Guido and others - JAN-MS-02735135	JAN-MS-02735135	Tewell 6	AU; H; PRE; R	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0695	Attachment - PPT slides Nucynta & Nucynta ER 2012 Marketing Strategies	JAN-MS-02735137	Tewell 7	PRE; R; AU; H	
S-0696	JAN-MS-00996343	JAN-MS-00996343	Tewell 8	No Document Produced with Deposition, LF; AU; 2043; R; H	
S-0697	6/19/14 Email from O. Bock to multiple recipients - JAN-MS-00996343	JAN-MS-00996343	Tewell 9	PRE; R; H; AU; LF	
S-0698	6/6-19/2014 PPT Slide Competitive Intelligence Bi-Weekly Brief JAN-MS-00996345	JAN-MS-00996345	Tewell 10	PRE; R; H; AU; LF	
S-0699	3/10/2015 Email from T. Davidson to P. Smykil and others - JAN-MS-00430614	JAN-MS-00430614	Tewell 11	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0700	12/18/2008 PPT Slides Chronic Pain Management Message Platform - JAN-MS-00298408	JAN-MS-00298408	Tewell 12	PRE; R; H; AU; LF	
S-0701	Johnson & Johnson Request For Proposal	JAN-MS-00298408	Tewell 13	R; PRE; CON; CU; AU; H; PRE; LF; PO, J-MIL-9	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0702	4/5/2014 Email from F. Tewell to T. Davidson - JAN-MS-00576394	JAN-MS-00576394	Tewell 14	PRE; R; AU	
S-0703	3/23/2016 Email from F. Tewell to S. Shadel - JAN-MS-00578079	JAN-MS-00578079	Tewell 15	AU; H; PRE; R	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0704	10/1/2015 Email from F. Tewell to F. Adkins - JAN-MS-01974211	JAN-MS-01974211	Tewell 16	PRE; R; AU	
S-0705	12/15/2015 Email from F. Tewell to Christinemussoo - JAN-MS-00578066	JAN-MS-00578066	Tewell 17	AU; H; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0739	7/18/2001 Email from P. Mehr to M. Kowalczyk, L. Brooks, L. Vicciardo - JAN-MS-0311528	JAN-MS-0311528		Chupa 9	H; R; PRE; LF	12 O.S. 2802
S-0740	11/5/2002 Email from C. Pavia to B. Amberg and K. Chupa - with attachment Ppt slides Duragesic Clinical Presentation-Psychological Abuse with Opioids 10-02 - JAN-MS-00786434	JAN-MS-00786434		Chupa 10	R; PRE; H; LF	12 O.S. 2401, 2402; 12 O.S. 2802
S-0741	6/4/2003 Email from J. Williams to K. Chupa and others - JAN-MS-00305112	JAN-MS-00305112		Chupa 11	H; R; PRE; LF	
S-0742	2/2/2005 Janssen - Important Correction of Drug Information - JAN-MS-00776286	JAN-MS-00776286		Chupa 12	R; PRE; H; LF	
S-0743	2/28/2000 Email from S. Zollo to K. Chupa re Purdue Frederick/I&J Co-promotion Meeting	JAN-MS-00246903		Chupa 13	H; R; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2802
S-0744	7/24/2012 Email from K. Chupa to N. Manna, L. David - JAN-MS-00246704	JAN-MS-00246704		Chupa 14	H; R; PRE; LF	12 O.S. 2802
S-0745	Johnson & Johnson Request For Proposal Exhibit Resignation e-mail			Chupa 15	R; PRE; CON; CU; AU; H; PRE; LF; PO, J-MIL-9	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0746	8/14/2012 Email from K. Chupa to A. Gorsky - JAN-MS-00775912	JAN-MS-00775912		Chupa 16	R; PRE	
S-0747	7/20/2017 PPT Slides U.S. Government Affairs Strategic Planning	Teva_OK_07846206		Judge 1	First Amendment; H; LF; R; T-MIL-10, PO, AU	12 O.S. 2802
S-0748	2/12/2003 Pain Care Management Meeting Attendees	POK003317376		Judge 2	AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0749	3/9/2018 Email from C. Mcginn to D. Judge - TEVA_OK_00910253	TEVA_OK_00910253		Judge 3	First Amendment; AU; H; R; T-MIL-10, AU	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0750	3/16/2018 Email from C. Mgiin to C. Baeder - TEVA_OK_00910287	TEVA_OK_00910287		Judge 4	First Amendment; AU; H; R; T-MIL-10, AU	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0751	3/27/2018 Email from C. Mcginn to D. Judge and J. Gardner	TEVA_OK_04856955		Judge 5	First Amendment; AU; H; R; T-MIL-10, AU	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0752	5/4/2018 Email from D. Judge to multiple recipients	TEVA_OK_02892186	TEVA_OK_02892193	Judge 6	First Amendment; AU; H; R; T-MIL-10, AU	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0753	MedPage Today - Chronic Pain Fuels Boom in Opioids							First Amendment; H; R; PRE; AU; PR/AU; LF; INC	12 O.S. 2401, 2402; 12 O.S. 2802
S-0754	Table 2.1 Comparison of DSM-IV, DSM-B and NSDUH Substance-Use Disorder Assessment							AU; H; R; PRE; PR/AU; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0755	Pseudoaddiction: Fact or Fiction?							First Amendment; Nuisance Statute's Safe-harbor; Preemption; AU; H; R; PRE; PR/AU; LF; 2701	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0756	Journal of Addictive Diseases - Prevalence of Prescription Opioid-Use Disorder Among Chronic Pain Patients							PRE; R; H; LF; AU; T-MIL-4	
S-0757	Making Pain Talk Painless	PDD8013710549						AU; LF; H	12 O.S. 2602, 12 O.S. 2901
S-0758	Pain Care Forum- 2010 Meeting Schedule	TEVA_OK_00116233						First Amendment; AU; H; PRE; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0759	Counseling Your Patients and Their Families Regarding the Use of Opioids to Relieve Pain	WISPPSG00008698						First Amendment; AU; H; PRE; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0760	Information on Opioid Dependence, Tolerance and Addiction	PKY180112565						First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0761	Expert Opinion - Efficacy and Safety of Tapentadol Extended Release for the Management of Chronic Low Back Pain	JAN-MS-00303825						First Amendment; AU; H; PRE; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0762	Opioids Manufactured, Owned and/or Developed by Janssen since 1996 (package inserts included)	JAN-MS-00074460						PRE; R; H; LF	
S-0763	Duragesic Risk Management Plans							H; PRE; R; SUM	12 O.S. 2802
S-0764	Index to Nucynta IR and ER Safety Surveillance Plan	JAN-MS-00213760						PRE; R; H; SUM	
S-0765	Responsible Opioid Prescribing Book	JAN-MS-00230429						PRE; R; H; SUM	
S-0766	Pain Products Learning System							H; R; PRE; INC	12 O.S. 2802
S-0767	"Approved Documents by Product"	TEVA OK 0026801						AU; H; LF; PO	12 O.S. 2602, 12 O.S. 2901;
S-0768	FAQ Listing	TEVA OK 00826186						H; AU; LF; PO	12 O.S. 2802
S-0769	FAQ About Actiq	TEVA OK 00823379						H; AU; LF; PO	12 O.S. 2802
S-0770	Two-page Nucynta website printout	TEVA 07226345						AU; H; LF; PO	12 O.S. 2602, 12 O.S. 2901;
								AU; H; PRE; R; PR/AU; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0771	Email from HCC Communications	JAN-MS-02000333	336	McGregor-Beck 2	PRE; R; H; AU; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0772	Johnson & Johnson Overview & Meeting Objectives	JAN-MS-00273413		McGregor-Beck 3	AU; H; PRE; R; LF	
S-0773	Department of Health & Human Services Facsimile to Roxanne McGregor-Beck	JAN-MS-00230364		McGregor-Beck 4	H; PRE; CON; CU; R; AU; LF	12 O.S. 2403; 12 O.S. 2802
S-0774	Copy Review Approval Form 0 Let's Talk Pain Video/Transcript - Myth v. Reality, Fishman	JAN-MS-00007320	326	McGregor-Beck	PRE; R; H; AU; LF	
S-0775	Copy Review Approval Form - Let's Talk Pain Video/Transcript - Getting Started	JAN-MS-00007215	221	McGregor-Beck 6	PRE; R; H; AU; LF	
S-0776	Copy Review Submission Cover Sheet	JAN-MS-00006865	6904	McGregor-Beck 7	PRE; R; H; AU; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0777		CONRAD000000006	CONRAD000000025	McGregor-Beck 8	AU; H; PRE; R; LF	
S-0778	Copy Review Approval Form - Guidebook on Pain Management	JAN-MS-00000330	343	McGregor-Beck 9	PRE; R; H; AU; LF	
S-0779	Copy Review Approval Form - Pain Management Script & DVD	JAN-MS-00000344	372	McGregor-Beck 10	PRE; R; H; AU; LF	
S-0780	Email from GV re Tramadol Legislation in Nebraska	JAN-MS-0249093		Vorsanger 1	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0781	March 2008 Agenda Update	JAN-MS-02149085		Vorsanger 2	First Amendment; H; PRE; R; AU; LF	12 O.S. 2802
S-0782	Generic Drugs Paper	JAN-MS-00641019		Vorsanger 3	First Amendment; AU; H; PRE; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0783	Subscription Services Agreement	JAN-MS-02102600		Vorsanger 4	AU; H; R; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0784	Second Amended Subscriptions Services Agreement	JAN-MS-02100624		Vorsanger 5	H; PRE; R; AU; LF	12 O.S. 2802
S-0785	Medical Development Project Statement	JAN-MS-00491920		Vorsanger 6	AU; H; PRE; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0786	"Euphoria v. Feeling Good" email	JAN-MS-00605609		Vorsanger 7	AU; H; PRE; R; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0787	Vorsanger personal friends with Portenoy email	JAN-MS-00337085		Vorsanger 8	Discovery Violations; AU; H; R; PRE; CON; CU; LF	12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0788	KOL categorization	JAN-MS-02337833		Vorsanger 9	AU; H; PRE; CON; CU; Privileged; R; LF	12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0789	SCEPTRE Duplicate Case Search	JAN-MS-02102667	Vorsanger 10	PRE; R; H; AU; LF; SUM	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0790	Janssen Speaker Trainer Meeting	JAN-MS-00314736	Vorsanger 11	AU; H; PRE; R; LF	12 O.S. 2802
S-0791	OMJSA Advisory Board Email	JAN-MS-02258276	Vorsanger 12	H; PRE; R; AU; LF	12 O.S. 2802
S-0792	Nucuynta FAQs	JAN-MS-00066073	Vorsanger 13	AU; H; PRE; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0793	Alza Memo	JAN-MS-021132383	Vorsanger 14	AU; H; R; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0794	Duragesic Package Insert		Vorsanger 15	H; PRE; R; AU; LF	12 O.S. 2802
S-0795	Risk Management for Our Products pwrpt	JAN-MS-02321524	Vorsanger 16	PRE; R; H; AU; LF	
S-0796	Duragesic Risk Mgmt Overview	JAN-MS-02305132	Vorsanger 17	PRE; R; H; AU; LF	
S-0797	Duragesic Risk Mgmt Plan	JAN-MS-00151777	Vorsanger 18	PRE; R; H; AU; LF	
S-0798	CU Review of Duragesic	JAN-MS-02754767	Vorsanger 19	PRE; R; H; AU; LF	
S-0799	Article: What percentage of chronic pain patients develop drug-related behaviors?		Vorsanger 20	H; PRE; R; AU; J-MIL-12, 2701	12 O.S. 2802
S-0800	Cochrane Library document		Vorsanger 21	H; PRE; R; AU; J-MIL-12, 2701	12 O.S. 2802
S-0801	Evaluation of Tamper Resistant properties		Vorsanger 22	H; PRE; R; AU; J-MIL-12, 2701	12 O.S. 2802
S-0802	Nucuynta Risk Evaluation and Mitigation Strategy	JAN-MS-01489228	Vorsanger 23	PRE; R; H; AU	
S-0803	Nucuynta Risk Evaluation and Mitigation Strategy: 4th Progress Report	JAN-MS-00228548	Vorsanger 24	PRE; R; H; AU; LF	
S-0804	LARRY WESTFALL BIOGRAPHY FROM PHARMAFORCE 2015		Westfall 1	AU; H; PRE; R	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0805	JULY 12, 2010 EMAIL IN RE: ALLIANCE SLIDE DECK FOR THURSDAY- JAN-MS-00399861	JAN-MS-00399861	Westfall 2	First Amendment; AU; H; R; PRE; J- MIL-3	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0806	Alliance Management presentation by Bing Caglungun and Larry Westfall	JAN-MS-00399862	Westfall 3	First Amendment; AU; H; R; PRE; J- MIL-3	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0807	JANUARY 25, 2011 E-MAIL IN RE: J&J CORPORATE MEMBERSHIP- JAN-MS- 00263139	JAN-MS-00263139	Westfall 4	First Amendment; AU; H; PRE; R; J- MIL-3	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0808	MARCH 9, 2010 E-MAIL IN RE: JCCR PAIN PROPOSAL	JAN-MS-00920885	Westfall 5	First Amendment; H; PRE; R; AU; J- MIL-3	12 O.S. 2802
S-0809	FINAL PAIN PROPOSAL 1.31.10 ATTACHMENT	JAN-MS-00920888	Westfall 6	First Amendment; AU; H; PRE; R; J- MIL-3	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0810	JUNE 16, 2011 E-MAIL IN RE: OM-NUC COLLABORATION OPPORTUNITIES	JAN-MS-00257679		Westfall 7	First Amendment; AU; H; PRE; R; J-MIL-3	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0811	JULY 6, 2010 E-MAIL IN RE: DEA COMMENT REQUEST	JAN-MS-00923191	JAN-MS-00923192	Westfall 8	First Amendment; AU; H; PRE; R; J-MIL-3	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0812	DECEMBER 2009 POWERPOINT TITLED HEALTH POLICY, ADVOCACY & QUALITY	JAN-MS-00932749		Westfall 9	First Amendment; AU; H; PRE; R; J-MIL-3	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0813	Partners Against Pain: The Relaunch	PKY180114954	PKY180115032	Must 1	First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0814	Rationale for Partners Against Pain Spinoff	PKY191998690		Must 2	First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0815	Purdue Answer to Def Pet.			Must 3	H; R	12 O.S. 2401, 2402; 12 O.S. 2802
S-0816	"Enhancing the Value of Purdue's Brand"	PKY183039429	PKY183039453	Must 4	R; PRE; CON; CU; AU; H; PRE; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0817	Oxycontin Clipboard			Must 5	First Amendment; AU; H; PRE; R; LF; T-MIL-4	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0818	Email With Tim Shea Alan Must	PPLPC030001004486	PPLPC030001004486	Must 6	AU; H; R; PRE; CON; CU; Privileged; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0819	Emails Between Alan Must and Matt Well	PPLPC031001533703	PPLPC031001533705	Must 7	First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0820	Emails Between Keith Wood and Alan Must	PPLPC031001533706	PPLPC031001533711	Must 8	AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0821	Partners Against Pain: Pain Advocacy Toolkit	PKY180142455	PKY180142525	Must 9	First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0822	Nichols Denzenhall Letter	PKY181306617	PKY181306617	Must 10	AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0823	Partners Against Pain: Grassroots Advocacy Program	PKY180108971	PKY180108986	Must 11	First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0824	Leadership Summit on Pain Management	PKY18030001		Must 12	First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0825	2001 Performance Plan	PKY180282177	PKY180282187	Must 13	AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0826	Heroic Dopeheads	PKY183403079		Must 14	AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0827	Email between Robin Hogen and Merle Spiegel	PKY183403079		Must 15	AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0828	Notice of Deposition			Hassler 1	H	12 O.S. 2802
S-0829	Topics 1&2 Outline			Hassler 2	First Amendment; R; PRE; CON; CU; AU; H; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0830	US Policy 120	TEVA_OK_00510745-51-754		Hassler 3	First Amendment; AU; H; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0831	Golin Harris - Teva Advocacy Mapping: Identifying Advocacy Partners to Enhance Patient Care	TEVA_OK_00101615-101721		Hassler 4	First Amendment; AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0832	Marketing Contract Review/Signoff	TEVA_OK_005076707-5076714		Hassler 5	First Amendment; AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0833	8/3/04 Letter, AAPM to MediCom	TEVA_OK_00104823-104824		Hassler 6	First Amendment; AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0834	MediCom Worldwide, Inc. Letter of Agreement	TEVA_OK_00105193-105194		Hassler 7	First Amendment; AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0835	Educational Grant Draft Request	TEVA_OK_00513368-513418		Hassler 8	First Amendment; AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0836	APF Consensus Statement in Support of H.R. 1020	APF2072-2075		Hassler 9	First Amendment; AU; H; PRE; R; LF; Scope	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0837	6/8/12 Letter, FSMB to Senators Baucus, Grassley	FSMB000000017		Hassler 10	First Amendment; AU; H; PRE; R; LF; Scope	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0838	American Pain Society	AFS-MDL000000001-47		Hassler 11	First Amendment; AU; H; PRE; R; LF; Scope	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0839	6/8/12 Letter, American Academy of Pain Medicine to Senators Grassley, Baucus	AAPM000000005		Hassler 12	First Amendment; AU; H; PRE; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0840	Pain Care Forum	JAN-MS-00992093		Hassler 13	PRE; R; H; LF; AU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0841	Email "wont sell itself"	TEVA OK 03563715		Baeder 1	AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0842	Core Team Meetig Agenda	TEVA OK 00911162		Baeder 2	AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0843	Teva Product Catalog			Baeder 3	AU; H; R; LF; INC	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0844	Teva Product Catalog (filtered)			Baeder 4	AU; H; R; LF; INC	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0845	Teva Product Catalog (filtered)			Baeder 5	AU; H; R; LF; INC	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0846	Teva Generics Website printout			Baeder 6	AU; H; R; LF; INC; PR/AU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0847	Teva Generics Website printout			Baeder 7	AU; H; R; LF; INC; PR/AU	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0848	Team weekly call email notes	TEVA OK 00770384		Baeder 8	AU; H; R; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0849	Opana Article			Baeder 9	AU; H; R; PRE; CON; CU; LF; PR/AU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0850	Oxycodone Product Email	TEVA OK 01250518		Baeder 10	H; R; AU; LF	12 O.S. 2401, 2402; 12 O.S. 2802
S-0851	IMS "heard what she wanted to hear"	TEVA OK 07960539		Baeder 11	AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0852	Bad Baeder Behavior on call	TEVA OK 07960544		Baeder 12	AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0853	"Part 2 lol" email	TEVA OK 00900939		Baeder 13	AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0854	Order Totals	TEVA OK 03432976		Baeder 14	AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0855	Excessive Usage	TEVA OK 00893531		Baeder 15	AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0856	Generic Weekly Tracking email	Teva OK 01969888		Baeder 16	H; R; AU; LF	12 O.S. 2401, 2402; 12 O.S. 2802
S-0857	Teva Settlement Agreement	TEVA OK 05039942		Baeder 17	AU; H; R; LF; PRE T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0858	Purdue Teva Distribution Supply Agreement	TEVA OK 00898620		Baeder 18	AU; H; R; LF; PRE T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0859	DEA Excessive Usage	TEVA OK 00893531		Baeder 19	AU; H; R; LF; PRE T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0860	Teva Code of Conduct			Baeder 20	AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0861	Email with "2013" Fentora SOW" attachment	TEVA_OK_04802703		Hassler 14	First Amendment; AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0862	Email dated 5-5-2013 from J. Jacobs to K. Teno	TEVA_OK_00666963		Hassler 15	First Amendment; AU; H; R; LF; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0863	Picture of Tom Cruise			Hassler 16	AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0864	Deposition Notice of Additional Topics			Hassler 17	R; PRE; CU	
S-0865	2003 Actiq Marketing Plan	TEVA_OK_00107392		Hassler 18	AU; H; R; LF; Scope	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0866	Actiq Master Plan	TEVA_OK_00094174		Hassler 19	AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0867	2010 Tactical Recommendations	TEVA_OK_00067262		Hassler 20	AU; H; R; LF; Scope	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0868	Request by MediCom Worldwide	TEVA_OK_00105111		Hassler 21	AU; H; R; LF; Scope	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0869	Medscape Letter Agreement	TEVA_OK_00104670		Hassler 22	AU; H; R; LF; Scope	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0870	Dannemiller Grant	TEVA_OK_00521274		Hassler 23	AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0871	Fentora Speaker Utilization, March 2007	TEVA_OK-00740562		Hassler 24	AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0872	Fentora 2015 Speaker Bureau Detailed Rationale	TEVA_OK_00504691		Hassler 25	AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0873	2003 Program Honorarium by Speaker	TEVA_OK_00755596		Hassler 26	AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0874	Pain Franchise Public Relations 2006 Budget Supplement	TEVA_OK_01022263		Hassler 27	AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0875	Actiq MEP 2002 Document	TEVA_OK_06130495		Hassler 28	AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0876	List of Speaker Events between 2006 and 2015	TEVA_OK_00099767		Hassler 29	AU; H; R; LF; IC	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0877	Enlarged version of the first page of Exhibit 29	TEVA_OK_00099767		Hassler 29A	H; R; AU; LF; INC	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0878	Russell Portenoy CV		Portenoy 1	Discovery Violations; H; R; PRE; J-MIL-14		12 O.S. 2802
S-0879	Declaration of Russell Portenoy		Portenoy 2	Discovery Violations; First Amendment; Nuisance Statute's Safe-harbor; Preemption; R; PRE; CON; CU; H; PRE; R; J-MIL-14; LF		12 O.S. 2403; 12 O.S. 2802
S-0880	Nucynta & Nucynta ER Business Plan	JAN-MS-0010801	Portenoy 3	Discovery Violations; AU; H; PRE; R; LF		12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0881	Duragesic Marketing Update	JAN-MS-00310227			Portenoy 4	AU; H; R; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0882	Dept. of Pain and Palliative Care 10 Yr anniversary	OKExpert-000005834			Portenoy 5	Discovery Violations; H; PRE; CON; CU; AU; LF	12 O.S. 2403; 12 O.S. 2802
S-0883	De-designated Tas Alk. Slides				Portenoy 6	Discovery Violations; Nuisance Statute's Safe-harbor; AU; H; R; PRE; CON; CU; LF; J-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0884	Cephalon Guilty Plea				Portenoy 7	R; PRE; CON; CU; AU; PRE; H; PO; T-MIL-5	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901
S-0885	Reuters News Release: Insys CEO Pleads Guilty				Portenoy 8	Discovery Violations; AU; H; R; PRE; CON; CU; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0886	FDA requests removal of Opana ER				Portenoy 9	Discovery Violations; AU; H; R; PRE; CON; CU; PR/AU; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0887	Speaker List for Duragesic	JAN-MS-00312595			Portenoy 10	Discovery Violations; AU; H; R; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0888	Summary of Payments in resp to SFC	JAN-OK-00144146			Portenoy 11	Discovery Violations; First Amendment; AU; H; PRE; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0889	Beth isreal Inv	JAN-MS-00394856			Portenoy 12	Discovery Violations; AU; H; PRE; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0890	Beth isreal Inv	JAN-MS-00394856			Portenoy 13	Discovery Violations; AU; H; PRE; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0891	Beth isreal Inv	JAN-MS-00931728			Portenoy 14	Discovery Violations; AU; H; R; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0892	TRIM Archiving Cover Memo	Teva-OK-01483802			Portenoy 15	Discovery Violations; AU; H; R; LF; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0893	APS Clinical Practice Guidelines	RP_000139			Portenoy 16	Discovery Violations; First Amendment; PRE; R; H; AU; LF	
S-0894	Sloan Kettering Acceptance of Speaker Invitation letter	PKY180606606	PKY180606606		Portenoy 17	Discovery Violations; AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0895	Reading Hospital Grant Letter	PKY180606605	PKY180606605		Portenoy 18	Discovery Violations; AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0896	HSGAC Fueling an Epidemic				Portenoy 19	Discovery Violations; First Amendment; AU; H; PRE; R; LF; T-MIL-1	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0897	TAX info for RKP	RP_000001			Portenoy 20	Discovery Violations; First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0898	TRx High correlated to call activity graphic	PKY183117989			Portenoy 21	Discovery Violations; AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-0899	targeting high prescribers slide	PDD8901061478	PDD8901061479		Portenoy 22	Discovery Violations; AU; H; R; PRE; CON; CU; LF; T-MIL-4; INC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-0900	APS Consensus Statement				Portenoy 23	Discovery Violations; First Amendment; H; R; PRE; AU; LF	12 O.S. 2401, 2402; 12 O.S. 2802
S-0901	Porter and Jack (full page)				Portenoy 24	Discovery Violations; H; LF; AU	12 O.S. 2802
S-0902	Purdue Corporate Responsibility Statement	PPLP004281019			Portenoy 25	Discovery Violations; AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-0903	Durgestic High Decile Prescribers	JAN-MS-00311782			Portenoy 26	Discovery Violations; AU; H; PRE; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0904	Janssen Marketing Research Document	JAN-MS-00778989			Portenoy 27	PRE; R; H; AU; LF	
S-0905	Fentora commercialization update	TEVA_OK_00041816			Portenoy 28	Discovery Violations; AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0906	CDC Charts for increase of opioid use				Portenoy 29	Discovery Violations; AU; H; R; PRE; LF; PR/AU; T-MIL-1, SUM	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0907	State not adding Portenoy to our suit email				Portenoy 30	Discovery Violations; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0908	Portenoy Chronic Use of Opioids Article				Portenoy 31	Discovery Violations; H; R; AU	12 O.S. 2401, 2402; 12 O.S. 2802
S-0909	Appropriate Opioid Pharmacotherapy				Portenoy 32	Discovery Violations; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0910	Duragesic Label				Portenoy 33	AU; H; R; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0911	Emerging Practices Robyn Kohn email	JAN-MS-00392797			Portenoy 34	Discovery Violations; AU; H; PRE; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0912	Portenoy's Motion to Dismiss				Portenoy 35	Discovery Violations; R; PRE; CON; CU; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403
S-0913	Letter from RKP to Purdue re new position	PDD1701554611	PDD1701554613		Portenoy 36	Discovery Violations; AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-0914	Letter re RKP participation in a symposium	PDD1701430618			Portenoy 37	Discovery Violations; AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-0915	RKP letter to Goldenheim	PPLPC037000009388	PPLPC037000009390		Portenoy 38	Discovery Violations; AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-0916	Letter from Purdue to RKP appointing him as an opioid advisory board member	PPLPD004322853			Portenoy 39	Discovery Violations; AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-0917	RKP isnt represented by Purdue email	PPLPD004341334			Portenoy 40	Discovery Violations; AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-0918	Fentanyl REMS Assessment				Portenoy 41	Discovery Violations; H; R	12 O.S. 2401, 2402; 12 O.S. 2802
S-0919	Actavis Acquires Kadian				Portenoy 42	Discovery Violations; AU; H; R; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-0920	Brian Ercole Morgan Lewis partner page				Portenoy 43	Discovery Violations; AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-0921	Amended Protective Order				Robin 1		
S-0922	OSU Powerpoint on Pharm. Conflicts of Interest				Robin 2	First Amendment; R; PRE; CON; CU; AU; H; PRE; R; LF	12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-0923	FSMB Websit Screenshot				Robin 3	First Amendment; AU; PRE; R; H; LF; SUM	12 O.S. 2602; 12 O.S. 2901
S-0924	6/8/2012 Letter to Baucas from FSMB	FSMB00000017			Robin 4	First Amendment; AU; H; R; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-0925	PCF 2017 Meetings Schedule	TWILLMAN 010141	TWILLMAN 010155		Robin 5	First Amendment; AU; PRE; R; H; LF	12 O.S. 2602; 12 O.S. 2901
S-0926	FSMB Participation in PCF Email LR w/ BR	PPLP004087167	PPLP004087168		Robin 6	First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-0927	Pain Care Forum Directory	POK003341641			Robin 7	First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802

S-0928	June 11th PCF Meeting	PPLP004052090	PPLP004052092	Robin 8		AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0929	PCF Agenda from B Rosen	WISPPSG00134349	WISPPSG00134349	Robin 9		AU; H; R; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0930	10/2013 PCF Communications working group update	PPLP004270333	PPLP004270335	Robin 10		AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0931	FSMB Press Release			Robin 11		First Amendment; AU; PRE; R; H; LF	12 O.S. 2602, 12 O.S. 2901
S-0932	Congressional Strategies workgroup email	PPLP004051254	PPLP004051256	Robin 12		First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0933	Model Guidelines Production	PKY181678252		Robin 13		AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0934	Anthony Picaro Sales Note/Memo	PKY182313612	PKY182313612	Robin 14		AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0935	Workshop on Pain Mangement and Policy	NPRO00001TPP000001342		Robin 15		AU; H; R; PRE; LF; J-MIL-12	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0936	Responsible Opioid Prescribing			Robin 16		AU; H; R; PRE; INC	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0937	Purdue Distribution Model Policy	PPLPC03000017694		Robin 17		AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0938	FSMBFred Friendly Seminar	PPLPC030000176727	PPLPC030000176729	Robin 18		First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0939	Medical Liason Monthly Report	PPLPC036000044733	PPLPC036000044752	Robin 19		AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0940	AAPM Day Three and Four Summary	JAN-MS-00928114		Robin 20		First Amendment; AU; H; R; PRE; LF; J-MIL-12	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0941	Customer Performance Report from FSMB	FSMB000000001	FSMB000000014	Robin 21		AU; H; PRE; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0942	Ok State Board of Osteo Examiners Quarterly Meeting Minutes			Robin 22		First Amendment; AU; H; LF	12 O.S. 2602, 12 O.S. 2901

S-0943	2008 Email Chain	PPLP004086828	PPLP004086829	Robin 23	First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0944	Use Guidelines for Chronic Use of Analgesics			Robin 24	AU; H; R; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0945	CDC Guidelines			Robin 25	Nuisance Statute's Safe-harbor; Preemption; AU; H; R; PRE; LF; PR/AU; T-MIL-1, SUM	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0946	Tapentadol Break Through Barriers to treatment	JAN-MS-00500135		Panico 1	First Amendment; Judicial Estoppel; R; PRE; CON; CU; AU; H; PRE; R; LF	12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0947	APS PR Pain Policy Slide Deck	JAN-MS-00500562		Panico 2	PRE; R; H; AU; LF	
S-0948	Tapentadol PR Initiatives	JAN-MS-00500563		Panico 3	First Amendment; AU; H; PRE; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0949	Use of Opioid Analgesics in Pain Management			Panico 4	First Amendment; Nuisance Statute's Safe-harbor; Preemption; AU; H; PRE; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0950	CDC Prescribing Guidelines			Panico 5	Nuisance Statute's Safe-harbor; Preemption; AU; H; R; PRE; LF; PR/AU; T-MIL-1, SUM	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0951	Highlights of Prescribing info for Nucynta			Panico 6	AU; H; PRE; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0952	J&J RFP			Panico 7	R; PRE; CON; CU; AU; H; PRE; LF; PO, J-MIL-9	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0953	Presidents Comm. On Combating Opioids			Panico 8	H; R; PRE; AU; LF; PR/AU; T-MIL-1, SUM	12 O.S. 2401, 2402; 12 O.S. 2802
S-0954	What a Prescriber should know being writing their first prescription	JAN-MS-03090578		Panico 9	AU; H; PRE; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0955	MedPage Today - Chronic Pain Fuels Boom in Opioids			Panico 10	Discovery Violations; Nuisance Statute's Safe-harbor; Preemption; AU; H; PRE; R; PR/AU; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0956	Treating Chronic Pain Gourley article	JAN-MS-03090707		Panico 11	First Amendment; Judicial Estoppel; Nuisance Statute's Safe-harbor; Preemption; R; PRE; CON; CU; AU; H; R; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0957	Lets Talk Pain Coalition email	JAN-MS-01239405		Panico 12	First Amendment; AU; H; PRE; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-0958	Pain Advocacy Coalition Kickoff Meeting	JAN-MS-01239406							12 O.S. 2602, 12 O.S. 2901;
S-0959	Copy Review Submission	JAN-MS-00006865			Panico 13		First Amendment; AU; H; PRE; R; LF	PRE; R; H; AU; LF	12 O.S. 2802
S-0960	2009 budget requests for tapentadol	JAN-MS-00276491			Panico 15		PRE; R; H; AU; LF		
S-0961	Tapentadol Medscape coverage	JAN-MS-00822496			Panico 16		AU; H; PRE; R; LF		12 O.S. 2602, 12 O.S. 2901;
S-0962	Highlights of prescribing information Duragesic				Panico 17		AU; H; PRE; R; LF		12 O.S. 2802
S-0963	CNN email story	JAN-MS-00483191			Panico 18		Judicial Estoppel; Nuisance Statute's Safe-harbor; Preemption; R; PRE; CON; CU; AU; H; PRE; R; LF		12 O.S. 2602, 12 O.S. 2901;
S-0964	Pain Portfolio Strategy Email	JAN-MS-03064268			Panico 19		First Amendment; AU; H; PRE; R; LF		12 O.S. 2802
S-0965	Ortho-McNeil Stmt about Duragesic	JAN-MS-01245617			Panico 20		R; PRE; CON; CU; H; PRE; AU; LF		12 O.S. 2403; 12 O.S. 2802
S-0966	Pain Mgmt Update Fentanyl patch	JAN-MS-02755899			Panico 21		First Amendment; Nuisance Statute's Safe-harbor; Preemption; R; PRE; CON; CU; AU; H; R; PRE; LF		12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0967	Email	JAN-MS-00481527			KDE 1		PRE; R; H; AU; LF; J-MIL-12		
S-0968	Medical Affairs Analgesia - Medical Science Liason Report	JAN-MS-01203019			KDE 2		PRE; R; H; AU; LF		
S-0969	Summary of Payment Made 1997-2012 in Response to Senate Finance Committee Request dated 6/8/12				KDE 3		PRE; R; H; AU; LF		
S-0970	Email	JAN-MS-00285031			KDE 4		R; PRE; CON; CU; AU; H; PRE; LF		12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0971	Proposed Target KOLs fro PPR Communications	PPLP004268991			KDE 5		AU; H; R; PRE; CON; CU; LF; T-MIL-4		12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0972	Tapentadol Team Status - 6/24/09 - Acute Pain Publications	JAN-MS-003323309			KDE 6		AU; H; PRE; R; LF		12 O.S. 2602, 12 O.S. 2901;
S-0973	Email	JAN-MS-005050508			KDE 7		First Amendment; AU; H; PRE; R; LF		12 O.S. 2802
S-0974	Use of Opioid Analgesis in Pain Management	JAN-MS-03090610			KDE 8		PRE; R; H; AU; LF		12 O.S. 2602, 12 O.S. 2901;